1
|
Koo CY, Zheng H, Tan LL, Foo LL, Shih E, Hausenloy DJ, Soo RA, Wong AS, Richards AM, Lee CH, Chan MY. Global Registry of Acute Coronary Events Score Underestimates Post-Acute Coronary Syndrome Mortality among Cancer Patients. Cancers (Basel) 2023; 15:5222. [PMID: 37958396 PMCID: PMC10648565 DOI: 10.3390/cancers15215222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 10/22/2023] [Accepted: 10/26/2023] [Indexed: 11/15/2023] Open
Abstract
Background Patients with prior cancer are at increased risk of acute coronary syndrome (ACS) with poorer post-ACS outcomes. We aimed to ascertain if the Global Registry of Acute Coronary Events (GRACE) score accurately predicts mortality risk among patients with ACS and prior cancer. Methods We linked nationwide ACS and cancer registries from 2007 to 2018 in Singapore. A total of 24,529 eligible patients had in-hospital and 1-year all-cause mortality risk calculated using the GRACE score (2471 prior cancer; 22,058 no cancer). Results Patients with prior cancer had two-fold higher all-cause mortality compared to patients without cancer (in-hospital: 22.8% versus 10.3%, p < 0.001; 1-year: 49.0% vs. 18.7%, p < 0.001). Cardiovascular mortality did not differ between groups (in-hospital: 5.2% vs. 4.8%, p = 0.346; 1-year: 6.9% vs. 6.1%, p = 0.12). The area under the receiver operating characteristic curve of the GRACE score for prediction of all-cause mortality was less for prior cancer (in-hospital: 0.64 vs. 0.80, p < 0.001; 1-year: 0.66 vs. 0.83, p < 0.001). Among patients with prior cancer and a high-risk GRACE score > 140, in-hospital revascularization was not associated with lower cardiovascular mortality than without in-hospital revascularization (6.7% vs. 7.6%, p = 0.50). Conclusions The GRACE score performs poorly in risk stratification of patients with prior cancer and ACS.
Collapse
Affiliation(s)
- Chieh-Yang Koo
- Department of Cardiology, National University Heart Centre Singapore, Singapore 119074, Singapore
| | - Huili Zheng
- Clinical Research Unit, Khoo Teck Puat Hospital, Singapore 768828, Singapore
| | - Li-Ling Tan
- Department of Cardiology, National University Heart Centre Singapore, Singapore 119074, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore
| | - Ling-Li Foo
- National Registry of Diseases Office, Health Promotion Board, Singapore 168937, Singapore
| | - E’Ching Shih
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore
| | - Derek J. Hausenloy
- Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore
- National Heart Research Institute Singapore, National Heart Centre, Singapore 169609, Singapore
- The Hatter Cardiovascular Institute, University College London, London WC1E 6HX, UK
- Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taichung 41354, Taiwan
| | - Ross A. Soo
- Department of Haematology-Oncology, National University Cancer Institute of Singapore, Singapore 119074, Singapore; (R.A.S.)
| | - Alvin S. Wong
- Department of Haematology-Oncology, National University Cancer Institute of Singapore, Singapore 119074, Singapore; (R.A.S.)
| | - Arthur M. Richards
- Department of Cardiology, National University Heart Centre Singapore, Singapore 119074, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore
- Christchurch Heart Institute, University of Otago, Dunedin 9016, New Zealand
| | - Chi-Hang Lee
- Department of Cardiology, National University Heart Centre Singapore, Singapore 119074, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore
| | - Mark Y. Chan
- Department of Cardiology, National University Heart Centre Singapore, Singapore 119074, Singapore
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore
| |
Collapse
|
2
|
Tan JY, Chia YW, Chan M, Lim SL, Chin C, Yap J, Richards AM, Teo ZW, Amanullah MR, Peck KH, Choo TLJ, Sim HW, Young BE, Macary P, Yeo KK. Pathophysiologic mechanism for MYOcarditis in COVID-19 VAccinations ("MYOVAx" Study). Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): NMRC COVID-19 Research Fund
Objective
This is the first prospective cohort study in Singapore to investigate the COVID-19 vaccine-associated myocarditis to understand its pathophysiology.
Introduction
Acute myocarditis and other cardiovascular symptoms have been observed to be associated with the two mRNA-based coronavirus disease 2019 (COVID-19) vaccines—namely Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273)—currently in-use in Singapore. The mechanisms through which myocarditis occurs are unknown, hence our study aims to understand the pathophysiology of myocarditis associated with COVID-19 vaccines.
Methods
Patients with onset of cardiac manifestations were recruited from multiple hospital outpatient clinics between November 2021 and September 2022. Clinical history and physical examination data was collected with blood sample collection, echocardiography, 12-lead electrocardiogram (ECG), coronary angiography and magnetic resonance imaging (MRI) at recruitment and 6-month follow-up. Analysis of biomarkers, genetic, serological and MRI data was conducted.
Results
As of 6 September 2022, a total of 5 patients have been enrolled (4 males, 1 female). The most commonly reported symptoms across all patients were chest pain/discomfort (80%), followed by palpitations (40%). MRI evidence of myocarditis has been detected in 2 (50%) of the male patients, of which both reported two or more symptoms occurring 1-2 days post-vaccination. Both patients have each received at least two doses of either the Pfizer-BioNTech BNT162b2 vaccine or Moderna mRNA-1273 vaccine. Their MRI findings were consistent with myocarditis. On late gadolinium enhancement (LGE) imaging, epicardial enhancement at the basal inferolateral segment and mid-wall enhancement at the apical anterior, lateral and inferior walls were observed in one patient. Patchy, mid-wall LGE in the basal inferior/inferolateral wall was observed in the other patient. No MRI evidence of myocarditis was available for the sole female patient.
Conclusion
While more data is needed to definitively prove the association of the two mRNA-based Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 COVID-19 vaccines with post-vaccination myocarditis, we believe our findings may support further investigations to enable risk stratification for vaccine-associated myocarditis and identify potential preventative strategies accordingly.
Collapse
Affiliation(s)
- J Y Tan
- National Heart Centre Singapore, Department of Cardiology , Singapore , Singapore
| | - Y W Chia
- Tan Tock Seng Hospital, Department of Cardiology , Singapore , Singapore
| | - M Chan
- National University Heart Centre, Department of Cardiology , Singapore , Singapore
| | - S L Lim
- National University Hospital, Department of Cardiology , Singapore , Singapore
| | - C Chin
- National Heart Centre Singapore, Department of Cardiology , Singapore , Singapore
| | - J Yap
- National Heart Centre Singapore, Department of Cardiology , Singapore , Singapore
| | - A M Richards
- National University Hospital, Cardiovascular Research Institute , Singapore , Singapore
| | - Z W Teo
- Changi General Hospital, Department of Cardiology , Singapore , Singapore
| | - M R Amanullah
- Sengkang General Hospital, NHCS Cardiology @ SKH , Singapore , Singapore
| | - K H Peck
- Khoo Teck Puat Hospital, Department of Cardiology , Singapore , Singapore
| | - T L J Choo
- KK Women's and Children's Hospital, Cardiology Service , Singapore , Singapore
| | - H W Sim
- Ng Teng Fong General Hospital, Department of Medicine , Singapore , Singapore
| | - B E Young
- National Centre for Infectious Diseases , Singapore , Singapore
| | - P Macary
- National University of Singapore, Department of Microbiology and Immunology , Singapore , Singapore
| | - K K Yeo
- National Heart Centre Singapore, Department of Cardiology , Singapore , Singapore
| |
Collapse
|
3
|
Chew-Harris J, Kuan WS, Ibrahim I, Chan SP, Li Z, Liew OW, Appleby S, Frampton C, Troughton R, Chong JPC, Tan LL, Lin W, Ooi SBS, Richards AM, Pemberton CJ. Comparative performances of soluble urokinase plasminogen activator receptor and Mid-regional proADM to predict composite death and new heart failure rehospitalisation in acutely breathless patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Soluble urokinase plasminogen activator receptor (suPAR) is a pleotropic receptor, capable of orchestrating plaque vulnerability and vascular immune dysfunction. Mid-regional pro-adrenomedullin (MR-proADM) is the stable peptide precursor of adrenomedullin, with concentrations reflective of vasodilation and cardiac remodelling. We compared the prognostic performances of suPAR and MR-proADM for the composite clinical endpoint of death and new heart failure (HF) in patients with undifferentiated breathlessness.
Methods
Patients presenting to hospital with the primary complaint of acute dyspnoea were recruited in New Zealand (n=612) and in Singapore (n=483)]. Baseline plasma measurements were undertaken for suPAR (ViroGates) and MR-proADM (Thermo Scientific). Cardiac biomarker levels of NT-proBNP (Roche) was available on all patients. Statistical assessment was made using SPSS v28 (IBM), with all biomarkers treated as continuous variables and presented as median [interquartile range (IQR)]. Prognostic performance of suPAR, MR-proADM and NT-proBNP to predict the composite clinical endpoint of death/new HF at 90-days and 1-yr were assessed using receiver operator curve (ROC) area under the curve (AUC) analysis (Z-scores) and Cox hazard regression analysis (per doubling of biomarker concentrations) after adjustment for traditional risk factors. P-value <0.05 was considered statistically significant.
Results
In the entire acutely breathless cohort [median age: 65 years (IQR: 52.9–76.0), 63.1% males], 343/1095 of patients had the final adjudication of ADHF. suPAR and MR-proADM concentrations were higher with increasing age (Spearmans rho, r>0.46, P<0.0001), lower eGFR (r>0.58, P<0.0001) and in those with ADHF (r>0.40, P<0.0001). During the follow-up period, 122 patients were categorised with death/new HF by 90-days, rising to 281 at 1-year. suPAR and MR-proADM were able to predict death/new HF at 90-days (both ROC-AUC >0.77) and at 1-year (both ROC-AUC ≥0.78) (Table 1). All markers were however less accurate in predicting this endpoint in the presence of ADHF (ROC-AUC <0.71). After adjustment in Cox-regression modelling, suPAR obtained HR >1.35 per doubling of suPAR concentrations (P=0.001) for outcomes at 90-days and at 1-year (Table 2), achieving the highest prognostic performance for this clinical endpoint, followed by NT-proBNP (HR >1.29) (Table 2), whilst MR-proADM was not an independent predictor of death/HF in this cohort. suPAR was also an independent predictor of death/HF for patients with ADHF, obtaining HR >1.35 per doubling of concentrations. Above a cut-off concentration of 3.6 ng/mL, suPAR was associated with a HR of 2.1 (95% CI: 1.55–2.91) for death/HF at 1-year for acutely dyspnoeic patients.
Conclusion
suPAR concentrations is superior than MR-proADM in predicting the clinical end-point of death/HF at 1-year in this cohort. It may aid in risk-stratification strategies for the management of acutely breathless patients.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): National Heart Foundation of New ZealandHealth Research Council of New Zealand
Collapse
Affiliation(s)
- J Chew-Harris
- University of Otago Christchurch, Medicine , Christchurch , New Zealand
| | - W S Kuan
- National University Health System , Singapore , Singapore
| | - I Ibrahim
- National University Health System , Singapore , Singapore
| | - S P Chan
- National University Heart Centre , Singapore , Singapore
| | - Z Li
- National University Health System , Singapore , Singapore
| | - O W Liew
- National University Heart Centre , Singapore , Singapore
| | - S Appleby
- University of Otago Christchurch, Medicine , Christchurch , New Zealand
| | - C Frampton
- University of Otago Christchurch, Medicine , Christchurch , New Zealand
| | - R Troughton
- University of Otago Christchurch, Medicine , Christchurch , New Zealand
| | - J P C Chong
- National University Heart Centre , Singapore , Singapore
| | - L L Tan
- National University Heart Centre , Singapore , Singapore
| | - W Lin
- National University Heart Centre , Singapore , Singapore
| | - S B S Ooi
- National University Health System , Singapore , Singapore
| | - A M Richards
- University of Otago Christchurch, Medicine , Christchurch , New Zealand
| | - C J Pemberton
- University of Otago Christchurch, Medicine , Christchurch , New Zealand
| |
Collapse
|
4
|
Lewis L, Raudsepp S, Whitlow J, Appleby S, Pemberton C, Richards AM. Do more specific assays for B-type natriuretic peptides better predict heart failure in breathless patients than the currently used assays? Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehab849.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Heart Foundation of New Zealand Health Research Council of New Zealand
Introduction
The cardioprotective B-type natriuretic peptide (BNP1-32) and its inactive congener N-terminal proBNP1-76 (NTBNP1-76) are produced from their precursor peptide proBNP, proportionate to cardiac dysfunction, underpinning their now-universal endorsement as markers for heart failure (HF) diagnosis. ProBNP concentrations are also increased in patients with HF. BNP1-32 is difficult to measure in plasma due to its low concentration and short half-life. Thus, less specific BNP and NT-proBNP assays are routinely used in the diagnosis and prognosis of HF. However, these assays also variably detect proBNP, BNP metabolites, and glycosylated proBNP or glycosylated NT-proBNP. How well these assays compare to highly specific assays that only detect BNP1-32 or NTBNP1-76 has not been assessed.
Purpose
We will compare the performance of assays specific for BNP1-32 and NTBNP1-76 only with that of a less specific commercially available NT-proBNP assay that is widely used for the diagnosis of heart failure.
Methods
Plasma samples obtained from patients presenting to the Emergency Department with breathlessness (n = 195) were assayed using a commercially available NT-proBNP assay and our specific in-house BNP1-32 (1) and NTBNP1-76 (2) assays. The diagnostic performance for clinically adjudicated acute HF (AHF, 60/195 patients, 31%) was assessed for each assay using receiver operator curve (ROC) analysis.
Results
Median (IQR) concentrations (n = 195) of NT-proBNP (101.7 [29.7, 353] pmol/L) and NTBNP1-76 (108.6 [25, 442] pmol/L) were markedly higher than BNP1-32 concentrations (1.9 [0.3-6.6] pmol/L) (p < 0.001 for both comparisons). Peptide concentrations were higher in patients with heart failure (n = 60) than those without heart failure for NT-proBNP (559 [247,1097] vs 46 [16,123] pmol/L), NTBNP1-76 (441.9 [155,1205] vs 37.9 [15,131] pmol/L) and BNP1-32 (7.8 [4,17] vs 0.5 [0.2,2.4] pmol/L) (all P < 0.001).
NT-proBNP assay results were highly correlated with our specific NTBNP1-76 and BNP1-32 assays (Spearman’s rho = 0.91 and 0.92, respectively, both P < 0.001, n = 195).
NT-proBNP, NTBNP1-76 and BNP1-32 assays performed similarly in the diagnosis of AHF (AUC [95%CI] = 0.88 [0.84-0.93], 0.85 [0.79-0.91] and 0.89 [0.84-0.94] respectively (all p < 0.001).
Discussion
Despite the differences in assay specificity all 3 assays performed similarly in the diagnosis of AHF in patients presenting with breathlessness.
Conclusions
All three assays diagnosed heart failure similarly, providing evidence that the widely used NT-proBNP assay can reliably be used as a proxy for active BNP1-32 in the diagnosis of acute heart failure. Whether this less specific NT-proBNP assay and our specific NTBNP1-76 and BNP1-32 assays (i) offer similar prognostic information and whether (ii) their marker performance is differentially altered by common confounders including age, renal dysfunction, obesity and atrial fibrillation, remain to be ascertained.
Collapse
Affiliation(s)
- L Lewis
- University of Otago Christchurch, Christchurch, New Zealand
| | - S Raudsepp
- University of Otago Christchurch, Christchurch, New Zealand
| | - J Whitlow
- University of Otago Christchurch, Christchurch, New Zealand
| | - S Appleby
- University of Otago Christchurch, Christchurch, New Zealand
| | - C Pemberton
- University of Otago Christchurch, Christchurch, New Zealand
| | - A M Richards
- University of Otago Christchurch, Christchurch, New Zealand
| |
Collapse
|
5
|
Chin C, Le TT, Singh G, Yip J, Chai SC, Yong QW, Lee E, Yeo D, Tay E, Goh PP, Ling LF, Richards AM, Delgado V, Ding ZP, Ling LH. Echocardiographic global longitudinal strain as a marker of myocardial fibrosis predicts outcomes in aortic stenosis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Left ventricular global longitudinal strain (LV-GLS) by speckle tracking echocardiography (STE) reflects intrinsic myocardial function, influenced by interstitial abnormalities. Cardiovascular magnetic resonance (CMR) detects myocardial fibrosis non-invasively, but it is limited for widespread use. We aim to establish LV-GLS as a marker of replacement myocardial fibrosis on CMR and validate the prognostic value of LV-GLS thresholds associated with fibrosis.
Methods
LV-GLS thresholds of replacement fibrosis were established in the derivation cohort: 151 patients (57±10 years; 58% males) with hypertension who underwent STE to measure LV-GLS and CMR for replacement myocardial fibrosis. Prognostic value of the thresholds was validated in a separate outcome cohort: 261 patients with moderate-severe aortic stenosis (AS; 71±12 years; 58% males; NYHA functional class I-II) and preserved LVEF ≥50%. Primary outcome was a composite of cardiovascular mortality, heart failure hospitalization, myocardial infarction and cerebrovascular events.
Results
In the derivation cohort, LV-GLS demonstrated good discrimination (c-statistics 0.74; 95% confidence interval: 0.66–0.83; P<0.001) and calibration (Hosmer-Lemeshow X2=6.37; P=0.605) for replacement fibrosis. In the outcome cohort, 52 events occurred over 16 [3.1, 42.0] months of follow-up. Patients with LV-GLS >−15.0% (corresponding to 95% specificity to rule-in myocardial fibrosis) had the worst outcomes compared to patients with LV-GLS <−21.0% (corresponding to 95% sensitivity to rule-out myocardial fibrosis) and those between −21.0 and −15.0% (log-rank P<0.001; Figure 1). Furthermore, LV-GLS offered independent prognostic value over clinical variables, AS severity, echocardiographic LVEF and E/e' (hazard ratio 1.18; 95% confidence interval: 1.07 to 1.30; P=0.001).
Conclusions
LV-GLS thresholds associated with replacement myocardial fibrosis is a novel approach to risk-stratify patients with AS and preserved LVEF (Figure 2).
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Medical Research Council Figure 1Figure 2
Collapse
Affiliation(s)
- C Chin
- National Heart Centre Singapore (NHCS), Singapore, Singapore
| | - T T Le
- National Heart Centre Singapore (NHCS), Singapore, Singapore
| | - G Singh
- Leiden University Medical Center, Department of Cardiology, Leiden, Netherlands (The)
| | - J Yip
- National University Heart Centre, Singapore, Singapore
| | - S C Chai
- Changi General Hospital, Singapore, Singapore
| | - Q W Yong
- Tan Tock Seng Hospital, Singapore, Singapore
| | - E Lee
- Tan Tock Seng Hospital, Singapore, Singapore
| | - D Yeo
- Apex Heart Center, Singapore, Singapore
| | - E Tay
- Asian Heart and Vascular Center, Singapore, Singapore
| | - P P Goh
- Asian Heart and Vascular Center, Singapore, Singapore
| | - L F Ling
- Khoo Teck Puat Hospital, Singapore, Singapore
| | - A M Richards
- National University Heart Centre, Singapore, Singapore
| | - V Delgado
- Leiden University Medical Center, Department of Cardiology, Leiden, Netherlands (The)
| | - Z P Ding
- National Heart Centre Singapore (NHCS), Singapore, Singapore
| | - L H Ling
- National University Heart Centre, Singapore, Singapore
| |
Collapse
|
6
|
Wang P, Zhou Y, Richards AM. Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry. Am J Cancer Res 2021; 11:8771-8796. [PMID: 34522211 PMCID: PMC8419061 DOI: 10.7150/thno.62642] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Accepted: 07/30/2021] [Indexed: 12/18/2022] Open
Abstract
The approval of the first small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post-transcriptional gene regulator, are also the subject of both basic research and clinical trials. Both siRNA and miRNA mimics are ~21 nucleotides RNA duplexes inducing mRNA silencing. Given the well performance of siRNA, researchers ask whether miRNA mimics are unnecessary or developed siRNA technology can pave the way for the emergence of miRNA mimic drugs. Through comprehensive comparison of siRNA and miRNA, we focus on (1) the common features and lessons learnt from the success of siRNAs; (2) the unique characteristics of miRNA that potentially offer additional therapeutic advantages and opportunities; (3) key areas of ongoing research that will contribute to clinical application of miRNA mimics. In conclusion, miRNA mimics have unique properties and advantages which cannot be fully matched by siRNA in clinical applications. MiRNAs are endogenous molecules and the gene silencing effects of miRNA mimics can be regulated or buffered to ameliorate or eliminate off-target effects. An in-depth understanding of the differences between siRNA and miRNA mimics will facilitate the development of miRNA mimic drugs.
Collapse
|
7
|
Tan ESJ, Chan SP, Liew OW, Chong JPC, Leong GKT, Yeo DPS, Ong HY, Jaufeerally F, Yap J, Sim D, Ng TP, Ling LH, Lam CSP, Richards AM. Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. Clin Chem 2021; 67:216-226. [PMID: 33279970 DOI: 10.1093/clinchem/hvaa287] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Accepted: 10/28/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Consideration of circulating biomarkers for risk stratification in heart failure (HF) is recommended, but the influence of atrial fibrillation (AF) on prognostic performance of many markers is unclear. We investigated the influence of AF on the prognostic performance of circulating biomarkers in HF. METHODS N-terminal pro-B-type natriuretic peptide (NT-proBNP), mid-regional-pro-atrial natriuretic peptide, C-type natriuretic peptide (CNP), NT-proCNP, high-sensitivity troponin-T, high-sensitivity troponin-I, mid-regional-propeptide adrenomedullin, co-peptin, growth differentiation factor-15, soluble Suppressor of Tumorigenicitiy (sST2), galectin-3, and procalcitonin plasma concentrations were measured in a prospective, multicenter study of adults with HF. AF was defined as a previous history of AF, and/or presence of AF/flutter on baseline 12-lead electrocardiogram. The primary outcome was the composite of HF-hospitalization or all-cause mortality at 2 years. RESULTS Among 1099 patients (age 62 ± 12years, 28% female), 261(24%) patients had AF. Above-median concentrations of all biomarkers were independently associated with increased risk of the primary outcome. Significant interactions with AF were detected for galectin-3 and sST2. In considering NT-proBNP for additive risk stratification, sST2 (adjusted hazard ratio [AHR]1.85, 95%confidence interval [C.I.] 1.17-2.91) and galectin-3 (AHR1.85, 95%C.I. 1.09-2.45) were independently associated with increased primary outcome only in the presence of AF. The prognostic performance of sST2 was also stronger in AF for all-cause mortality (AF: AHR2.82, 95%C.I. 1.26-6.21; non-AF: AHR1.78, 95% C.I. 1.14-2.76 without AF), while galectin-3 predicted HF-hospitalization only in AF (AHR1.64, 95%C.I. 1.03-2.62). CONCLUSIONS AF modified the prognostic utility of selected guideline-endorsed HF-biomarkers. Application of markers for prognostic purposes in HF requires consideration of the presence or absence of AF. CLINICAL TRIAL REGISTRATION ACTRN12610000374066.
Collapse
Affiliation(s)
- Eugene S J Tan
- National University Heart Centre, Singapore.,Yong Loo Lin School of Medicine, National University, Singapore
| | - Siew-Pang Chan
- National University Heart Centre, Singapore.,Yong Loo Lin School of Medicine, National University, Singapore
| | - Oi-Wah Liew
- Yong Loo Lin School of Medicine, National University, Singapore
| | - Jenny P C Chong
- Yong Loo Lin School of Medicine, National University, Singapore
| | | | - Daniel P S Yeo
- Department of Cardiology, Tan Tock Seng Hospital, Singapore
| | - Hean-Yee Ong
- Department of Cardiology, Khoo Teck Puat Hospital, Singapore
| | - Fazlur Jaufeerally
- Department of Internal Medicine, Singapore General Hospital.,Duke-NUS Graduate Medical School, Singapore
| | - Jonathan Yap
- Department of Cardiology, National Heart Centre, Singapore
| | - David Sim
- Duke-NUS Graduate Medical School, Singapore.,Department of Cardiology, National Heart Centre, Singapore
| | - Tze-Pin Ng
- Yong Loo Lin School of Medicine, National University, Singapore
| | - Lieng-Hsi Ling
- National University Heart Centre, Singapore.,Yong Loo Lin School of Medicine, National University, Singapore
| | - Carolyn S P Lam
- Duke-NUS Graduate Medical School, Singapore.,Department of Cardiology, National Heart Centre, Singapore.,University Medical Centre Groningen, Netherlands
| | - Arthur M Richards
- National University Heart Centre, Singapore.,Christchurch Heart Institute, University of Otago, New Zealand.,Cardiovascular Research Institute, National University Health System, Singapore
| |
Collapse
|
8
|
Poh KK, Shabbir A, Ngiam JN, Lee PSS, So J, Frampton CM, Pemberton CJ, Richards AM. Plasma Clearance of B-Type Natriuretic Peptide (BNP) before and after Bariatric Surgery for Morbid Obesity. Clin Chem 2020; 67:662-671. [PMID: 33788936 DOI: 10.1093/clinchem/hvaa308] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 11/05/2020] [Indexed: 11/12/2022]
Abstract
BACKGROUND Obese patients have lower plasma concentrations of the cardiac natriuretic peptides (NPs) than their age- and sex-matched counterparts. This may reflect lower production and/or increased peptide clearance. It is unclear whether NP bioactivity is affected by obesity. METHODS We studied the effects of obesity on B-type natriuretic peptide (BNP) clearance and bioactivity by comparing results from standardized intravenous infusions of BNP administered 2 weeks before and 6 months after bariatric surgery in 12 consecutive patients with morbid obesity (body mass index, BMI > 35 kg/m2). Anthropometric, clinical, neurohormonal, renal, and echocardiographic variables were obtained pre- and postsurgery. Pre- vs postsurgery calculated intrainfusion peptide clearances were compared. RESULTS BMI (44.3 ± 5.0 vs 33.9 ± 5.2 kg/m2, P < 0.001) and waist circumference (130.3 ± 11.9 vs 107.5 ± 14.7 cm, P < 0.001) decreased substantially after bariatric surgery. Calculated plasma clearance of BNP was reduced (approximately 30%) after surgery. Though not controlled for, sodium intake was presumably lower after bariatric surgery. Despite this, preinfusion endogenous plasma NP concentrations did not significantly differ between pre- and postsurgery studies. The ratio of plasma N-terminal (NT)-proBNP to 24 h urine sodium excretion was higher postsurgery (P = 0.046; with similar nonsignificant findings for BNP, atrial NP (ANP) and NT-proANP), indicating increased circulating NPs for a given sodium status. Mean plasma NP concentrations for given calculated end-systolic wall stress and cardiac filling pressures (as assessed by echocardiographic E/e') rose slightly, but not significantly postsurgery. Second messenger, hemodynamic, renal, and neurohormonal responses to BNP were not altered between studies. CONCLUSION Obesity is associated with increased clearance, but preserved bioactivity, of BNP.
Collapse
Affiliation(s)
- Kian Keong Poh
- Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore.,Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - Asim Shabbir
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.,Department of Surgery, National University Hospital, Singapore
| | | | | | - Jimmy So
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.,Department of Surgery, National University Hospital, Singapore
| | | | | | - Arthur M Richards
- Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore.,Yong Loo Lin School of Medicine, National University of Singapore, Singapore.,Department of Medicine, National University Health System, Singapore.,Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
| |
Collapse
|
9
|
Lewis L, Raudsepp SD, Yandle TG, Frampton CM, Richards AM, Prickett TCR, Doughty R, Pemberton CJ. 150 ProBNP glycosylation of threonine 71 is increased with obesity in patients with heart failure. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehz872.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
The National Heart Foundation of New Zealand
Background
Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Plasma levels of B-type natriuretic peptide (BNP) or its amino terminal congener (NT-proBNP) are used for HF diagnosis and risk stratification. Circulating levels of both BNP and NT-proBNP are reduced by obesity and this phenomenon is one of the key weaknesses of the diagnostic performance of the natriuretic peptides in HF. Formation of BNP from enzymatic cleavage of proBNP1-108 between residues 76 and 77 by corin and/or furin is influenced by the degree of proBNP glycosylation, therefore we investigated the relationship between proBNP glycosylation, plasma NT-proBNP and body mass index (BMI) in HF patients.
Methods
Three assays were developed to distinguish between total proBNP (glycosylated plus non-glycosylated proBNP), proBNP not glycosylated at threonine 71 (NG-T71) and proBNP not glycosylated in the central region (NG-C). Intra and inter-assay CVs were <15%, limits of detection were <2 pmol/L and samples diluted in parallel.
Results
Applying these assays and an NT-proBNP assay to plasma samples from 106 healthy volunteers and 238 patients with HF determined that concentrations (median(IQR)) of proBNP, NG-T71 and NT-proBNP were greater in HF patients compared to controls (24.9 (3.6-55), 9.4 (1.5-21) and 212 (104-409) pmol/L vs 3.0 (1.5-19), 3.0 (1.5-14.5) and 4.7 (2-8) pmol/L respectively, all p < 0.012). NG-C was undetectable in most samples. ProBNP levels in HF patients with BMI above and below 30 kg/m2 were not different (21.9 (2.6-70) pmol/L and 25.7 (3.9-53) pmol/L respectively, p = 0.85), whereas HF patients with BMI > 30 had lower NT-proBNP and NG-T71 levels (121 (64-248) and 3 (1.5-16) pmol/L verse 271 (178-486) and 13.5 (1.5-24.2) pmol/L respectively, p < 0.003) and higher proBNP:NT-proBNP and proBNP:NG-T71 ratios (p = 0.001 and p = 0.02 respectively) than those with BMI < 30.
Discussion and Conclusion
Using three new assays specific for different glycosylated forms of proBNP we have shown that the processing of proBNP is dysregulated in heart failure compared to controls due to increased glycosylation at threonine 71 of proBNP. Obese patients with HF have even greater dysregulation, demonstrated by decreased concentrations of proBNP that is not glycosylated at T71 (NG-T71), and concomitant decreases in NT-proBNP. Thus, we have shown for the first time that increased BMI is associated with increased proBNP glycosylation at T71 in patients with heart failure. Glycosylation-induced impairment of proBNP processing explains, at least in part, the reduction in plasma concentrations of B-type cardiac natriuretic peptides observed in obesity. Using these assays to evaluate the proBNP profile of larger patient cohorts will further develop understanding of the relationships between BNP production, BMI and heart failure pathogenesis, which would be expected to lead to increased diagnostic performance.
Collapse
Affiliation(s)
- L Lewis
- University of Otago Christchurch, Christchurch, New Zealand
| | - S D Raudsepp
- University of Otago Christchurch, Christchurch, New Zealand
| | - T G Yandle
- University of Otago Christchurch, Christchurch, New Zealand
| | - C M Frampton
- University of Otago Christchurch, Christchurch, New Zealand
| | - A M Richards
- University of Otago Christchurch, Christchurch, New Zealand
| | - T C R Prickett
- University of Otago Christchurch, Christchurch, New Zealand
| | - R Doughty
- The University of Auckland, Auckland, New Zealand
| | - C J Pemberton
- University of Otago Christchurch, Christchurch, New Zealand
| |
Collapse
|
10
|
Sock Hwee T, Koh HWL, Chua JY, Yang XX, Ong CC, Teo L, Choi HW, Pilbrow AP, Pickering JW, Troughton RW, Doughty RN, Richards AM, Chan MY. P5719Plasma proteomics identify plaque-related proteins that predict long-term recurrent coronary events in patients with acute coronary syndrome. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Coronary plaque burden and composition drive recurrent ischaemic events in coronary artery disease.
Purpose
We first investigated the association between plasma proteins and coronary plaque characteristics in a cohort of asymptomatic individuals with low-intermediate Framingham Risk Score. Plaque-related proteins were further evaluated in a second cohort of patients with acute coronary syndrome (ACS) to determine their prognostic value for predicting future myocardial infarction (MI).
Methods
We profiled 1305 plasma proteins using an aptamer-based array (SOMAscan) in asymptomatic individuals who had undergone 384-slice coronary computed tomography angiography. Plaques were categorized by composition as calcified or non-calcified. First, we identified proteins that were different (based on multiple testing adjusted p-values: q-value <0.05) between 250 ACS patients who suffered a recurrent MI event on follow-up compared with another 250 ACS patients who remained event-free using Mann-Whitney U test. Next, protein candidates that also correlated (Pearson's p<0.05) with specific categories of plaque composition were evaluated using a cox proportional hazards model to determine the risk of recurrent MI, adjusting for potential confounders in the second cohort.
Results
A total of 65 and 120 plasma proteins were significantly associated with calcified and non-calcified plaques respectively in the asymptomatic cohort (N=79). Of these 185 proteins, 23 proteins were differentially expressed (DE) between ACS patients with and without recurrent MI events (median follow-up 1811 days). The top three up-and down-regulated proteins in the recurrent MI group were macrophage-capping protein, trefoil factor 3 and cystatin-SN (median FC 1.22, 1.17 and 1.17; q-value 4.34x10–6, 2.18x10–4, 3.17x10–3 respectively) and fibroblast growth factor 20, lymphotoxin a2/b1 and vascular endothelial growth factor receptor 2 (median FC 0.92, 0.94 and −0.090; q-value 1.31x10–3, 9.45x10–3 and 3.90x10–3) respectively. The quartiles of these protein concentrations were also associated with risk of recurrent MI, (log-rank test p-value range from 2.71x10–7 to 0.04). Of the DE proteins, the adjusted hazards ratio (HR) of cystatin-SN in the highest quartile (Q4) was 1.44 times that of the first quartile (Q1) (adjusted HR: 1.44, 95% CI: 0.93–2.2) and higher plasma concentration of cystatin-SN was associated with increasing risk of recurrent MI events (Trend test p=0.004). On the other hand, the highest quartile of fibroblast growth factor 20 was associated with 44% reduction in risks of recurrent MI adjusted HR: 0.56, 95% CI of HR: 0.35–0.87), with significant trend test (p=0.0096).
Conclusions
Large-scale plasma proteomics identified novel plaque-related proteins predictive of recurrent coronary events in patients with ACS. Further studies may help unravel the biological underpinnings of these circulating proteins and their potential as novel prognostic biomarkers.
Acknowledgement/Funding
This work was supported by grant NMRC/CSA-INV/0001/2016 from the National Medical Research Council, Singapore.
Collapse
Affiliation(s)
- T Sock Hwee
- National University of Singapore, Singapore, Singapore
| | - H W L Koh
- National University of Singapore, Singapore, Singapore
| | - J Y Chua
- National University Heart Centre, Singapore, Singapore
| | - X X Yang
- National University of Singapore, Singapore, Singapore
| | - C C Ong
- National University Heart Centre, Singapore, Singapore
| | - L Teo
- National University Heart Centre, Singapore, Singapore
| | - H W Choi
- National University of Singapore, Singapore, Singapore
| | - A P Pilbrow
- University of Otago Christchurch, Christchurch, New Zealand
| | - J W Pickering
- University of Otago Christchurch, Christchurch, New Zealand
| | - R W Troughton
- University of Otago Christchurch, Christchurch, New Zealand
| | - R N Doughty
- The University of Auckland, Department of Medicine, Auckland, New Zealand
| | - A M Richards
- National University of Singapore, Singapore, Singapore
| | - M Y Chan
- National University of Singapore, Singapore, Singapore
| |
Collapse
|
11
|
Pemberton CJ, Lee JA, Aldous S, Skelton L, Frampton CM, Than M, Troughton RW, Adamson P, Richards AM. P1756The protein APRIL predicts adverse outcomes in DAPT patients better than NT-proBNP and troponin. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Aim
Dual antiplatelet therapy (DAPT) is a mainstay of post-ACS treatment. However, prediction of adverse events in these patients needs improving. We show here that the TNFα-related protein APRIL (which is produced in platelets and atherosclerotic plaque) is a superior predictor of MACE and new MI in DAPT recipients post-ACS.
Methods
We prospectively recruited 518 patients presenting with the primary complaint of acute chest pain to our hospital ED. Patients were adjudicated to have ACS by 2 independent cardiologists in accordance with ESC guidelines with hsTnI as biomarker. Plasma EDTA samples taken at presentation and 2 hours after were interrogated for APRIL measurements using a two site ELISA. Clinical data/variables, standard biochemistry analytes, hsTnT and NT-proBNP were also measured. Statistical assessments were made using SPSS v23 (IBM). Data for all biomarkers were treated as continuous variables and are presented as median (interquartile range, (IQR)). Statistical assessment of the comparative diagnostic abilities of APRIL, hsTnT, NT-proBNP and hsTnI were assessed using receiver operator curve (ROC) area under the curve (AUC) analysis. The comparative power of each biomarker (log values) to predict new MACE, MI, bleeding and mortality in 1) the whole group and in 2) DAPT recipients alone, within 2 yrs of index presentation was undertaken using a logistic regression base model (95% CI) that included all clinical variables and hsTnI and hsTnT, with APRIL and NT-proBNP each included in additional multivariate analyses.
Results
Of the 518 recruited patients (median age 63 (IQR: 54–73, 35% female), 152 were adjudicated to have ACS (29%, 115 MI, 37 UAP). Presentation APRIL levels were higher in those with a cardiac versus non-cardiac cause for presentation (3.0, (2.0–4.7) vs. 2.4, (1.6–3.8) ng/mL, P=0.001) and positively correlated with hsTnT and NT-proBNP (all P<0.001), but it did not add to the hsTnI (ROC = 0.96) or hsTnT (ROC =0.92) assisted diagnosis of ACS. In all 518 patients, in the multivariate regression model, APRIL was a significant independent predictor of mortality (n=54, P=0.032), new MI (n=43, P=0.006), new ADHF (n=24, P=0.016) and MACE (n=71, P=0.005) that was additive to NT-proBNP and troponin. In DAPT recipients alone (n=156), APRIL was the only biomarker to independently predict new MI (n=27, 95% CI: 1.125–3.982, P=0.020) and MACE (n=37, 95% CI: 1.058–3.389, P=0.031). None of the markers, only age, predicted bleeding episodes.
Conclusion
APRIL is an platelet/plaque derived marker that provides independent risk assessment in ACS patients. In DAPT recipients, the ability of APRIL to predict new MI and MACE is superior to that of cardiac troponins and NT-proBNP and could be used to identify high risk individuals.
Acknowledgement/Funding
Health Research Council of New Zealand; Heart Foundation of New Zealand
Collapse
Affiliation(s)
- C J Pemberton
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - J A Lee
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - S Aldous
- Christchurch Hospital, Christchurch, New Zealand
| | - L Skelton
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - C M Frampton
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - M Than
- Christchurch Hospital, Christchurch, New Zealand
| | - R W Troughton
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - P Adamson
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - A M Richards
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| |
Collapse
|
12
|
Lim XC, Yatim SMJM, Chong SY, Wang X, Tan SH, Yang X, Chan SP, Richards AM, Charles CJ, Chan M, Wang JW. P4639Plasma tissue factor coagulation activity in post-acute myocardial infarction patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Coagulation is involved in fibroproliferative responses following acute myocardial infarction (AMI). Left ventricular (LV) remodeling following AMI is closely associated with progression to heart failure.
Purpose
We aimed to evaluate the association of plasma tissue factor (TF) coagulation activity with LV remodeling prior to heart failure in post-AMI patients.
Methods
This study was conducted in 228 subjects from the Post-AMI Left Ventricular Remodeling Biomarker Analysis (PAMILA) study and 57 healthy subjects. The post-AMI patients were divided into two age- and sex-matched groups: patients with adverse LV remodeling defined as an increase in LV end systolic volume by ≥15% over 6 months and patients with reverse LV remodeling defined as an decrease in LV end systolic volume by ≥15% over 6 months. TF coagulation activity was determined using human coagulation factor Xa generation based TF chromogenic activity assay and converted into concentrations of active TF (pM). Sodium-citrate anticoagulated plasma was collected at baseline (within 3 days after revascularization), 30 days and 6 months post-AMI. Results are presented as mean±S.E.M. One-way or two-way repeated measures ANOVA or a multiple multi-level longitudinal data analysis with structural equation model was used to assess differences in coagulation activity. P<0.05 was considered statistically significant.
Results
Plasma from healthy subjects and post-AMI patients at baseline had similar concentrations of active TF (TFa): 29.0±1.4 versus 29.1±0.7 pM. Patients treated with warfarin (15 out of 228 patients) showed lower plasma levels of TFa (mean difference −15.2 pM, [95% CI: −18.7, −11.7], p<0.001). Compared to baseline, plasma levels of TFa in the patients was significantly lower at 30 days post-AMI (mean difference −6.9 pM, [95% CI: −4.8, −8.9], p<0.001) and 6 months post-AMI (mean difference −2.8 pM, [95% CI: −0.8, −4.8], p=0.003). Intriguingly, plasma levels of TFa tended to recover from 30 days to 6 months post-AMI (mean difference 4.1 pM, [95% CI: 2.8, 5.4], p<0.001) toward the baseline level and the level in healthy subjects. Similar trends of temporal changes of plasma TFa levels were observed in patients with adverse LV remodeling and those with reverse LV remodeling although TFa levels were slightly higher in patients with reverse LV remodeling (F(2,448)=3.112, p=0.045 for interaction). After adjusting for age, gender, ethnicity, medications, lipid profile and risk factors, the temporal changes of plasma TFa levels in patients remain significant, however, the difference between patients with adverse versus reverse LV remodeling was not significant.
Conclusion
Plasma TF coagulation activity decreased post-AMI but did not differ in patients with adverse versus reverse LV remodeling.
Acknowledgement/Funding
National University Health System Singapore (NUHS O-CRG 2016 Oct-23) to JW Wang
Collapse
Affiliation(s)
- X C Lim
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - S M J M Yatim
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - S Y Chong
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - X Wang
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - S H Tan
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - X Yang
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - S P Chan
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - A M Richards
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - C J Charles
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - M Chan
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - J W Wang
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| |
Collapse
|
13
|
Wang JW, Yatim SMJM, Lim XC, Chong SY, Wang X, Tan SH, Yang X, Chan SP, Richards AM, Charles CJ, Chan MY. P2582Signature of plasma extracellular vesicles associated proteins in acute myocardial infarction patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Prediction of left ventricular (LV) remodeling post-acute myocardial infarction (AMI) remains challenging. Several circulating biomarkers have been associated with post-AMI LV remodeling, however, there is no biomarker available to distinguish adverse versus reverse LV remodeling.
Purpose
In this study, we aimed to assess the association of extracellular vesicles (EVs) associated proteins with LV remodeling post-AMI.
Methods
Plasma EVs were isolated via precipitation with dextran sulphate as we previously reported. The protein levels of EV associated von Willebrand factor (VWF), SerpinC1 (antithrombin-III), plasminogen and SerpinF2 (alpha 2-antiplasmin) were determined in the citrate-anticoagulated plasma from 57 healthy subjects and 200 patients recruited in the Post-AMI Left Ventricular Remodeling Biomarker Analysis (PAMILA) study. Patients were categorized into two groups: adverse LV remodeling (n=100) characterized by an increase or reverse LV remodeling (n=100) characterized by a decrease, in LV end systolic volume by ≥15% over 6 months. Patients' plasma was collected at baseline (within 3 days after percutaneous coronary intervention), 1 month and 6 months post-AMI. Log transformation of EV protein levels was performed for assessment in a multiple multi-level longitudinal data analysis with structural equation model (with level of significance fixed at 0.05).
Results
Compared to healthy subjects, baseline protein levels of EV associated VWF and SerpinF2 were significantly higher in post-AMI patients, whereas no difference was observed in SerpinC1 and plasminogen. Among the patients, those on statins (196 out of 200 patients) showed lower protein levels of EV associated VWF (p<0.001) and plasminogen (p=0.003), whereas patients treated with P2Y12 platelet inhibitors (195 out of 200 patients) showed higher protein levels of EV associated VWF (p=0.003) and plasminogen (p=0.035). Multiple multi-level longitudinal data analysis with structural equation model showed that protein levels of EV associated VWF (p<0.001) and SerpinC1 (p=0.021) were lower in patients with adverse LV remodeling than that in patients with reverse LV remodeling during the 6-month follow-up post-AMI. In contrast, protein levels of EV associated plasminogen (p=0.002) and SerpinF2 (p=0.002) were higher in patients with adverse LV remodeling. The differences in the four EV associated proteins between patients with adverse versus reverse LV remodeling remain significant after adjusting for age, gender, ethnicity, medications, lipid profile and risk factors (diabetes, hypertension, dyslipidemia and smoking).
Conclusions
Lower levels of EV associated coagulation proteins (VWF and SerpinC1) and higher levels of EV associated fibrinolytic proteins (plasminogen and SerpinF2) were presented in patients with adverse LV remodeling compared to those with reverse LV remodeling post-AMI.
Acknowledgement/Funding
National University Health System Singapore (NUHS O-CRG 2016 Oct-23) to JW Wang
Collapse
Affiliation(s)
- J W Wang
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - S M J M Yatim
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - X C Lim
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - S Y Chong
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - X Wang
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - S H Tan
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - X Yang
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - S P Chan
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - A M Richards
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| | - C J Charles
- National University of Singapore, Department of Surgery, Cardiovascular Research Institute (CVRI), Singapore, Singapore
| | - M Y Chan
- National University of Singapore, Department of Medicine and Cardiovascular Research Institute, Singapore, Singapore
| |
Collapse
|
14
|
Pemberton CJ, Lee JA, Aldous S, Appleby S, Chew-Harris J, Than M, Troughton RW, Richards AM. P3408The signal peptide of CNP is a novel predictor of MI, MACE and bleeding risk in chest pain patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Aim
CNP is an important vascular and cardiac derived member of the natriuretic peptide family. We have previously provided the first reports that the signal peptide of CNP (CNPsp) is present in the human circulation and is elevated in those with chest pain suspicious of ACS. Here, show that CNPsp levels are highly predictive of new MI, MACE and post-index bleeding in patients presenting with potential ACS.
Methods
We prospectively recruited 493 patients presenting with the primary complaint of acute chest pain to our hospital ED. Patients were adjudicated as ACS by 2 independent cardiologists in accordance with ESC guidelines with hsTnI as biomarker. Plasma EDTA samples taken at presentation and 2 hours after were interrogated for CNPsp measurements using our validated, specific assay. Clinical data/variables, standard biochemistry analytes, hsTnT and NT-proBNP (both Roche Cobas e411) were also measured. Statistical assessments were made using SPSS v23. Data for all biomarkers were treated as continuous variables and are presented as median (interquartile range, (IQR)). Statistical assessment of the comparative abilities of CNPsp, hsTnT, NT-proBNP and hsTnI (log values) to predict new MACE, MI, bleeding and mortality within 2 yrs of index presentation was undertaken using a logistic regression base model (95% CI) that included all clinical variables and hsTnI and hsTnT and NT-proBNP, with CNPsp added to into the multivariate analyses.
Results
Of the 493 recruited patients (median age 63 (IQR: 54–73, 35% female), 148 were adjudicated to have ACS (30%, 109 MI, 39 UAP). Presentation CNPsp levels were not higher in those with adjudicated ACS versus non-ACS (51, (45–65) vs. 50, (42–63) pmol/L, P=0.412), did not correlate with hsTnI, hsTnT or NT-proBNP, but were significantly lower in those with a history of MI (49, (42–59) vs. 51, (43–64) pmol/L, P=0.044). In contrast, they were significantly higher in those with ECG ST-depression (56, (47–85) vs. 50 (42–62) pmol/L, P=0.038). In the multivariate regression model of all 493 patients, lower values of CNPsp were a significant multivariate predictor of new MI (n=37, 95% CI: 0.06–0.89, P=0.038), MACE (n=64, 95% CI: 0.08–0.81, P=0.020) and new bleeding (n=40, 95% CI: 0.05–0.63, P=0.005) within 2 years of presentation. This predictive ability was additive and independent from NT-proBNP and troponin.
Conclusion
This is the first report that CNPsp measurement provides meaningful and independent risk assessment of important outcomes in ACS patients. In particular, the fact that lower levels of CNPsp are predictive of negative MI, MACE and bleeding outcomes suggests that CNPsp may have an unappreciated protective role in the cardiovascular system.
Acknowledgement/Funding
Health Research Council of New Zealand; Heart Foundation of New Zealand
Collapse
Affiliation(s)
- C J Pemberton
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - J A Lee
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - S Aldous
- Christchurch Hospital, Christchurch, New Zealand
| | - S Appleby
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - J Chew-Harris
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - M Than
- Christchurch Hospital, Christchurch, New Zealand
| | - R W Troughton
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| | - A M Richards
- University of Otago, Christchurch School of Medicine & Health Sciences, Christchurch, New Zealand
| |
Collapse
|
15
|
Chew-Harris JS, Appleby S, Richards AM, Troughton RW, Pemberton CJ. P2616Soluble urokinase plasminogen activator receptor (suPAR) predicts 1 year mortality in patients with acute breathlessness. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Aim
Soluble urokinase plasminogen activator receptor (suPAR) is a pleotropic receptor, capable of orchestrating plaque vulnerability and vascular immune dysfunction. Its concentration in circulation may reflect on CVD associated burden. We examined the prognostic ability of suPAR to predict death in patients suspicious of ADHF.
Methods
suPAR measurements were undertaken with a CE-marked ELISA (ViroGates) in 444 patients presenting to hospital with the primary complaint of breathlessness to our hospital ED. A second sample at 12–48 hours post ED admission was available for 378 patients. Standard biochemistry analytes; MR-proADM (BRAHMS), NTproBNP and hsTnT (both Roche) were also measured. Statistical assessment was made using SPSS v25 (IBM), with all biomarkers treated as continuous variables and presented as median [interquartile range (IQR)]. Group comparisons were made by Mann-Whitney U test. The singular or combined clinical performances of suPAR, NT-proBNP, hsTnT and MR-proADM were assessed using receiver operator curve (ROC) area under the curve (AUC) (Z-scores) and Cox hazard regression (log-values) analyses. P-value <0.05 was considered significant.
Results
In the breathless cohort [median age 72 yrs (IQR: 62–81, 43% female)], 35.1% had ADHF and 94/444 patients died within the 1st yr of ED presentation. In those who died within this 1st yr, median suPAR concentrations at both time-points; 5.2 ng/mL (IQR: 2.8–5.5) vs. 5.1 ng/mL (IQR: 1.7–2.3) were higher than those who did not die (3.5 ng/mL; IQR: 2.7–5.1) (P<0.0001). Plasma suPAR, for both time points, respectively, could predict death at 30d (n=22, ROC-AUC = 0.77 and 0.76), 90d (n=41, ROC-AUC = 0.77 and 0.75) and 1 yr (ROC-AUC = 0.73 and 0.72). Improvement in 90d mortality prediction was achieved with the inclusion of suPAR in models; for e.g. using ED values, for NTproBNP; ROC-AUC of 0.67 increased to 0.71, for hsTnT; ROC-AUC of 0.69 to 0.76, and for MR-proADM, ROC-AUC of 0.72 to 0.75. Both suPAR time-points (ROC-AUC 0.70) could predict 1 yr new heart failure (HF) (n=68) but did not assist in improving HF prediction when used in combination with NT-proBNP, hsTnT or MR-proADM. After adjustment for conventional risk factors, Cox hazard regression analyses however revealed suPAR as the only biomarker capable of predicting 1 yr mortality (P=0.005) with hazard ratios of 2.8 (CI: 1.4–5.9) and 3.5 (CI: 1.1–11.3) for the ED and inpatient time-points, respectively. In terms of best window for prognostic assessment, suPAR concentrations at ED, outperformed the inpatient concentrations as the superior time-point in predicting 1 yr mortality.
Conclusion
suPAR exhibits excellent prognostic ability in mortality prediction, proving better than NTproBNP, hsTnT and MR-proADM in acutely breathless patients. The usage of suPAR in complementary with current candidate cardiac biomarkers could dramatically improve the prognostic tools available to guide risk management in HF.
Acknowledgement/Funding
New Zealand Heart Foundation, Health Research Council of New Zealand
Collapse
Affiliation(s)
- J S Chew-Harris
- University of Otago Christchurch, Medicine, Christchurch, New Zealand
| | - S Appleby
- University of Otago Christchurch, Medicine, Christchurch, New Zealand
| | - A M Richards
- University of Otago Christchurch, Medicine, Christchurch, New Zealand
| | - R W Troughton
- University of Otago Christchurch, Medicine, Christchurch, New Zealand
| | - C J Pemberton
- University of Otago Christchurch, Medicine, Christchurch, New Zealand
| |
Collapse
|
16
|
Jiang X, Lew KS, Chen Q, Richards AM, Wang P. Human Mesenchymal Stem Cell-derived Exosomes Reduce Ischemia/Reperfusion Injury by the Inhibitions of Apoptosis and Autophagy. Curr Pharm Des 2019; 24:5334-5341. [DOI: 10.2174/1381612825666190119130441] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Accepted: 01/12/2019] [Indexed: 01/05/2023]
Abstract
Background:
Human mesenchymal stem cell-derived exosomes (hMSC-Exo) have been shown to
reduce ischemia/reperfusion injury (I/R) in multiple models. I/R-induced apoptosis or autophagy play important
roles in cell death. However, little or no reports demonstrate any roles of hMSC-Exo in this regards. Objective:
To test the hypothesis that the inhibition of I/R-induced apoptosis and autophagy play a pivotal role in the cardioprotection
of hMSC-Exo.
Methods:
Myoblast H9c2 cells and isolated rat hearts underwent hypoxia/re-oxygenate (H/R) or ischemia/
reperfusion (I/R) respectively. H9c2 were treated with 1.0 μg/ml Exo, in comparison with 3-MA or rapamycin
(Rapa), a known anti- or pro-autophagic agent respectively. Hearts were treated with 0.5, 1.0 and 2.0 μg/ml
Exo for 20 min in the beginning of reperfusion. Cell viability, WST assay, LDH release, Annexin-V staining
apoptosis assay and GFP-LC3 labeled autophagosomes formation, cardiac function and Western blot were measured.
Results:
Exo significantly reduced H/R injury as indicated by increased cell viability and reduced LDH and apoptosis.
3-MA, while Rapa, showed increased or decreased protective effects. Rapa-induced injury was partially
blocked by Exo. Exo decreased LC3-II/I ratio and increased p62, inhibited autophagosome formation, an indication
of autophagy inhibition. In isolated heart, Exo increased cardiac functional recovery and reduced LDH release
in I/R. Bcl-2 was significantly upregulated by Exo but not 3-MA. Exo downregulated Traf6 and upregulated
mTORC1/p-4eBP1.
Conclusion:
Exo reduce I/R-induced apoptosis and autophagy. Up-regulation of Bcl-2 is the cross-talk between
these two processes. The down-regulation of Traf6 and activation of mTORC1 are additional mechanisms in the
inhibition of apoptosis and autophagy.
Collapse
Affiliation(s)
| | - Kar-Sheng Lew
- Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Qiying Chen
- Huashan Hospital, Fudan University, Shanghai, China
| | - Arthur M. Richards
- Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Peipei Wang
- Cardiovascular Research Institute, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| |
Collapse
|
17
|
Jogia PM, Kalkoff M, Sleigh JW, Bertinelli A, La Pine M, Richards AM, Devlin G. NT-Pro BNP Secretion and Clinical Endpoints in Cardiac Surgery Intensive Care Patients. Anaesth Intensive Care 2019; 35:363-9. [PMID: 17591129 DOI: 10.1177/0310057x0703500307] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The primary objective of this study was to determine the pattern of N-Terminal pro brain natriuretic peptide (NT-pro BNP) secretion pre and post cardiac surgery and then to investigate the correlation between levels of serum NT-pro BNP and postoperative clinical and biochemical endpoints. This was a prospective observational study performed at a tertiary centre in New Zealand, examining 118 adult patients undergoing cardiac surgery. Interventions included blood samples for NT-Pro BNP and troponin-T taken 48 hours prior to operation and 12, 36 and 72 hours postoperatively. The plasma NT-pro BNP levels increased fourfold postoperatively, to plateau at 36 to 72 hours. Preoperative NT-pro BNP levels correlated with ventilation time (r=0.46), length of stay in intensive care unit (r=0.59), total perioperative noradrenaline dose (r=0.55), but not with postoperative atrial fibrillation or mortality. Using multivariate analysis, serum NT-pro BNP levels at 36 hours were associated with increased noradrenaline dose (P=0.001), decreased preoperative ejection fraction (EF) Group (P=0.013) and elevated preoperative NT-pro BNP (P <0.001). Factors not associated with NT-pro BNP levels at 36 hours include the operation type, bypass and cross-clamp times, use of milrinone and troponin-T. We conclude that NT-pro BNP levels increased markedly after cardiac surgery and that high preoperative NT-pro BNP levels are associated with a slow postoperative recovery, but do not predict the occurrence of postoperative atrial fibrillation or mortality. Myocardial ischaemia is an unlikely cause of the NT-pro BNP elevation, because no correlation existed between troponin-T and NT-pro BNP levels.
Collapse
Affiliation(s)
- P M Jogia
- Intensive Care Unit, Waikato Hospital, Hamilton, New Zealand
| | | | | | | | | | | | | |
Collapse
|
18
|
Zhou Y, Richards AM, Wang P. Abstract 268: Through the Inhibition of Autophagy Flux miR-221 Plays an Important Role in the Reductions of Hypoxia Reoxygenation Induced Cell Death and Collagen Synthesis in Cardiac Fibroblast. Circ Res 2018. [DOI: 10.1161/res.123.suppl_1.268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose:
We have previously reported that miR-221 protects myocytes against H/R-induced injury through the inhibitions of autophagy and apoptosis. It is not known has similar anti-autophagic and anti-apoptotic effects on cardiac fibroblast (cFB) and what role it plays in the regulation of cFB function.
Method:
Adult rat cFBs were isolated and transfected with miR-221 mimics and mimic control (miR-221 and MC). cFBs were subjected to normoxia (Nor) and H/R conditions. MiR-221 effects were monitored for cell injury (CCK8 and lactate dehydrogenase, LDH), apoptosis (Annexin V and 7-AAD staining), autophagy (LC3 and p62 by Western blot, WB) and collagen synthesis (Sircol). To study autophagy flux, Bafilomycin A1 (Baf) or Rapamycin (Rap) was applied to further inhibit or enhance autophagosome (ATGsome) formation and degradation respectively.
Results:
miRNA-221 increased cFB viability as indicated by increased CCK8 and reduced LDH release (miR-221 vs. MC) in H/R. This pro-survival effect did not involve apoptosis but reducing autophagy as indicated by unchanged Annexin V staining and reduced LC3-II/I ratio and increased p62 respectively. The protection was blocked by Rap. DMSO, the solvent used for the preparation of Baf and Rap, showed a significant induction of ATGsome formation on its own and override the anti-ATGsome formation effect of miR-221. In the presence of DMSO, miR-221 caused LC3 II accumulation, similar to the effect of Baf. In addition, miR-221 inhibited collagen synthesis as assessed by Sircol measurement. TGF-β, as a positive control, increased collagen synthesis significantly. The regulation of collagen synthesis of miR-221 and TGF-β could be abrogated by Rap and Baf respectively. Under Nor and H/R, the expressions of DDIT4 and Tp53inp1 were significantly downregulated by miR-221.
Conclusion:
Targeting on DDIT4 and Tp53inp1, miR-221 inhibited autophagy flux by reducing both ATGsome formation and degradation. The inhibition plays an important role in the protection of cFB and regulation of collage synthesis. This study reveals the complexity of cFB functional regulation by miRNA-221, preserving cFB in number without causing additional fibrosis. The unique feature of miR-221 might be an advantage in the treatment of cardiac infarction.
Collapse
Affiliation(s)
- Yue Zhou
- National Univ of Singapore, Singapore, Singapore
| | | | - Peipei Wang
- National Univ of Singapore, Singapore, Singapore
| |
Collapse
|
19
|
Wong LL, Saw EL, Lim JY, Zhou Y, Richards AM, Wang P. 4927MicroRNA Let-7d-3p contributes to cardiac protection via targeting HMGA2. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.4927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- L L Wong
- National University of Singapore, Medicine, Singapore, Singapore
| | - E L Saw
- National University of Singapore, Medicine, Singapore, Singapore
| | - J Y Lim
- National University of Singapore, Medicine, Singapore, Singapore
| | - Y Zhou
- National University of Singapore, Medicine, Singapore, Singapore
| | - A M Richards
- National University of Singapore, Medicine, Singapore, Singapore
| | - P Wang
- National University of Singapore, Medicine, Singapore, Singapore
| |
Collapse
|
20
|
Pilbrow AP, Templeton EM, Gamble GD, Wheeler NE, Frampton CM, Pearson JF, Sweet WE, Tang WHW, Moravec CS, Lund M, Devlin G, Troughton RW, Richards AM, Cameron VA, Doughty RN. P4761Genetic risk variants for heart failure onset and progression do not improve prediction of mortality beyond established prognostic neurohormonal and echocardiographic markers. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A P Pilbrow
- University of Otago Christchurch, Christchurch, New Zealand
| | - E M Templeton
- University of Otago Christchurch, Christchurch, New Zealand
| | - G D Gamble
- The University of Auckland, Auckland, New Zealand
| | - N E Wheeler
- University of Otago Christchurch, Christchurch, New Zealand
| | - C M Frampton
- University of Otago Christchurch, Christchurch, New Zealand
| | - J F Pearson
- University of Otago Christchurch, Christchurch, New Zealand
| | - W E Sweet
- Cleveland Clinic Foundation, Cleveland, United States of America
| | - W H W Tang
- Cleveland Clinic Foundation, Cleveland, United States of America
| | - C S Moravec
- Cleveland Clinic Foundation, Cleveland, United States of America
| | - M Lund
- Middlemore Hospital, Auckland, New Zealand
| | - G Devlin
- Waikato District Hospital, Waikato, New Zealand
| | - R W Troughton
- University of Otago Christchurch, Christchurch, New Zealand
| | - A M Richards
- University of Otago Christchurch, Christchurch, New Zealand
| | - V A Cameron
- University of Otago Christchurch, Christchurch, New Zealand
| | - R N Doughty
- The University of Auckland, Auckland, New Zealand
| |
Collapse
|
21
|
Nanayakkara S, Pemberton C, Patel H, Vizi D, Mak V, Richards AM, Mariani JA, Kaye DM. 1096Mid regional atrial natriuretic peptide is an independent predictor of peak pulmonary capillary wedge pressure in patients with heart failure with preserved ejection fraction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- S Nanayakkara
- The Alfred Hospital, Department of Cardiovascular Medicine, Melbourne, Australia
| | - C Pemberton
- University of Otago Christchurch, Christchurch Heart Institute, Christchurch, New Zealand
| | - H Patel
- The Alfred Hospital, Department of Cardiovascular Medicine, Melbourne, Australia
| | - D Vizi
- The Alfred Hospital, Department of Cardiovascular Medicine, Melbourne, Australia
| | - V Mak
- The Alfred Hospital, Department of Cardiovascular Medicine, Melbourne, Australia
| | - A M Richards
- University of Otago Christchurch, Christchurch Heart Institute, Christchurch, New Zealand
| | - J A Mariani
- The Alfred Hospital, Department of Cardiovascular Medicine, Melbourne, Australia
| | - D M Kaye
- The Alfred Hospital, Department of Cardiovascular Medicine, Melbourne, Australia
| |
Collapse
|
22
|
Pemberton CJ, Lee JA, Jardine R, Skelton L, Frampton CM, Troughton RW, Richards AM. P2791The TNF receptor TACI is a novel inflammatory predictor of heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- C J Pemberton
- University of Otago Christchurch, Christchurch, New Zealand
| | - J A Lee
- University of Otago Christchurch, Christchurch, New Zealand
| | - R Jardine
- University of Otago Christchurch, Christchurch, New Zealand
| | - L Skelton
- University of Otago Christchurch, Christchurch, New Zealand
| | - C M Frampton
- University of Otago Christchurch, Christchurch, New Zealand
| | - R W Troughton
- University of Otago Christchurch, Christchurch, New Zealand
| | - A M Richards
- University of Otago Christchurch, Christchurch, New Zealand
| | | |
Collapse
|
23
|
Tan E, Chan SP, Krishnan SK, Tan HC, Yeo TC, Low A, Lee RCH, Loh JPY, Loh PH, Tay ELW, Chan KH, Richards AM, Chan MY. P4619Accelerated accrural of ischaemic events after stopping dual antiplatelet therapy at 12 months in a real-world acute myocardial infarction cohort. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- E Tan
- National University Heart Centre, Singapore, Singapore
| | - S P Chan
- National University of Singapore, Singapore, Singapore
| | - S K Krishnan
- National University Heart Centre, Singapore, Singapore
| | - H C Tan
- National University Heart Centre, Singapore, Singapore
| | - T C Yeo
- National University Heart Centre, Singapore, Singapore
| | - A Low
- National University Heart Centre, Singapore, Singapore
| | - R C H Lee
- National University Heart Centre, Singapore, Singapore
| | - J P Y Loh
- National University Heart Centre, Singapore, Singapore
| | - P H Loh
- National University Heart Centre, Singapore, Singapore
| | - E L W Tay
- National University Heart Centre, Singapore, Singapore
| | - K H Chan
- National University Heart Centre, Singapore, Singapore
| | - A M Richards
- National University Heart Centre, Singapore, Singapore
| | - M Y Chan
- National University Heart Centre, Singapore, Singapore
| |
Collapse
|
24
|
Marshall AD, Bailey CG, Champ K, Vellozzi M, O'Young P, Metierre C, Feng Y, Thoeng A, Richards AM, Schmitz U, Biro M, Jayasinghe R, Ding L, Anderson L, Mardis ER, Rasko JEJ. CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic. Oncogene 2017; 36:4100-4110. [PMID: 28319062 PMCID: PMC5519450 DOI: 10.1038/onc.2017.25] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Revised: 12/21/2016] [Accepted: 01/05/2017] [Indexed: 12/14/2022]
Abstract
CTCF is a haploinsufficient tumour suppressor gene with diverse normal functions in genome structure and gene regulation. However the mechanism by which CTCF haploinsufficiency contributes to cancer development is not well understood. CTCF is frequently mutated in endometrial cancer. Here we show that most CTCF mutations effectively result in CTCF haploinsufficiency through nonsense-mediated decay of mutant transcripts, or loss-of-function missense mutation. Conversely, we identified a recurrent CTCF mutation K365T, which alters a DNA binding residue, and acts as a gain-of-function mutation enhancing cell survival. CTCF genetic deletion occurs predominantly in poor prognosis serous subtype tumours, and this genetic deletion is associated with poor overall survival. In addition, we have shown that CTCF haploinsufficiency also occurs in poor prognosis endometrial clear cell carcinomas and has some association with endometrial cancer relapse and metastasis. Using shRNA targeting CTCF to recapitulate CTCF haploinsufficiency, we have identified a novel role for CTCF in the regulation of cellular polarity of endometrial glandular epithelium. Overall, we have identified two novel pro-tumorigenic roles (promoting cell survival and altering cell polarity) for genetic alterations of CTCF in endometrial cancer.
Collapse
Affiliation(s)
- A D Marshall
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - C G Bailey
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - K Champ
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - M Vellozzi
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - P O'Young
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - C Metierre
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - Y Feng
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - A Thoeng
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - A M Richards
- Gynaecological Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| | - U Schmitz
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - M Biro
- Cell Motility and Mechanobiology, School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - R Jayasinghe
- Cancer Genomics, McDonnell Genome Institute, Washington University in St Louis, St Louis, MO, USA.,Division of Oncology, Department of Medicine, Washington University in St Louis, St Louis, MO, USA
| | - L Ding
- Cancer Genomics, McDonnell Genome Institute, Washington University in St Louis, St Louis, MO, USA.,Division of Oncology, Department of Medicine, Washington University in St Louis, St Louis, MO, USA
| | - L Anderson
- Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.,Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| | - E R Mardis
- Cancer Genomics, McDonnell Genome Institute, Washington University in St Louis, St Louis, MO, USA.,Division of Oncology, Department of Medicine, Washington University in St Louis, St Louis, MO, USA
| | - J E J Rasko
- Gene and Stem Cell Therapy Program, Centenary Institute, Camperdown, New South Wales, Australia.,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.,Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| |
Collapse
|
25
|
Abstract
Intraarticular phalangeal fractures are difficult to treat. The advantages of using dynamic external fixation devices include distraction of impacted fracture fragments and reduction in joint stiffness by allowing early joint mobilization. Previous reports have concentrated on pilon fractures and dorsal fracture dislocations affecting the proximal interphalangeal joint. We report our experience using a dynamic external spring fixator in the management of 15 patients with a variety of fracture patterns affecting the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints. In three cases the device spanned two adjacent joints. Long-term follow-up has shown excellent range of joint movement and no major complications. We consider that this device is an effective tool in the management of a range on complex intraarticular phalangeal fractures.
Collapse
Affiliation(s)
- D Johnson
- Department of Plastic and Reconstructive Surgery, Salisbury District Hospital, Odstock, Salisbury, Wiltshire SP2 8BJ, UK.
| | | | | | | |
Collapse
|
26
|
Carubelli V, Lombardi C, Lazzarini V, Bonadei I, Castrini AI, Gorga E, Richards AM, Metra M. N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. J Cardiovasc Med (Hagerstown) 2016; 17:828-39. [DOI: 10.2459/jcm.0000000000000419] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
27
|
Wang J, Wong LL, Richards AM, Chen YT. Abstract 414: Putative Role of MicroRNA-143 in Modulating Natriuretic Peptide Signaling via Down-regulation of the Expression of Natriuretic Peptide Receptor 3. Circ Res 2016. [DOI: 10.1161/res.119.suppl_1.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cardiac natriuretic peptides (NPs) play important roles in the regulation of intravascular blood volume and vascular tone. Among other clearance mechanisms, bio-active circulating NPs are removed by the clearance receptor, Natriuretic Peptide Receptor 3 (NPR3). We hypothesized that the level of NPR3 could be modulated by microRNAs (miRNAs) resulting in changes in the bioactivity of NPs. We have previously reported a cluster of miRNAs potentially regulating NPR3 expression. To extend these findings, expression of the microRNAs concerned was examined in multiple platforms, including plasma from a clinical heart failure cohort, in the rat myocardial infarction model, and in a human cardiac derived cell line subjected to hypoxic challenge.
Results:
miR-143 was up-regulated in peripheral blood in heart failure patients compared with controls. The binding of miR-143 to the 3’UTR of NPR3 m RNA was verified by luciferase reporter assay. Antagomir-based silencing of miR-143 enhanced NPR3 expression in human derived cardiac cells. Elevation of miR-143 and down-regulation of NPR3 levels were observed in hypoxia treated cells and in the myocardium from the rat myocardial infarction model. Taken together, these findings suggest miR-143 may be involved in the down-regulation of NPR3 which in turn may provide more cardiac protective bioactivity from NPs in heart failure, myocardial hypoxic stress and in myocardial infarction. In summary, NPR3 is negatively regulated by miR-143, pointing to the therapeutic potential of miR-143 to beneficially enhance NP responses.
Collapse
Affiliation(s)
- Juan Wang
- Cardiovascular Rsch Institute, National Univ Health System, Singapore, Singapore
| | - Lee L Wong
- Cardiovascular Rsch Institute, National Univ Health System, Singapore, Singapore
| | - Arthur M Richards
- Cardiovascular Rsch Institute, National Univ Health System, Singapore, Singapore
| | - Yei-Tsung Chen
- Cardiovascular Rsch Institute, National Univ Health System, Singapore, Singapore
| |
Collapse
|
28
|
Wong LL, Saw EL, Zhou Y, Wang P, Richards AM. Abstract 54: MicroRNA Let-7d-3p in Heart Failure. Circ Res 2016. [DOI: 10.1161/res.119.suppl_1.54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Circulating microRNA (miRNAs) levels are dysregulated in heart failure (HF) suggesting possible diagnostic and prognostic applications. In addition, miRNAs may yield insights into the pathophysiology of HF and provide targets for therapeutic intervention. We sought to identify the diagnostic utility of miRNAs in HF and to further investigate selected miRNAs as potential targets for therapeutic intervention. We hypothesized that distinct dysregulated circulating miRNAs in HF may be potential therapeutic targets to improve outcomes for HF.
Methods:
Plasma from 338 well-characterized HF patients and 208 age-matched controls were collected for qPCR based miRNA profiling. Selected miRNAs of interest were further investigated using myocyte cell line, H9C2 and primary neonatal rat ventricular cardiomyocytes, NRVM.
Results:
Seventy-four miRNAs (AUC>0.65, p<0.001) were significantly dysregulated for discrimination of HF from non-HF controls on receiver-operator analysis. Seven miRNAs of interest were selected for further investigation. Of these, let-7d-3p had the most up regulated miRNA fold change=1.32 (p<0.001 after FDR). Functional screening using mimic transfection demonstrated that let-7d-3p mimic increased CCK-8 activity and decreased LDH release in both H9C2 and NRVM during hypoxia. By in silico target prediction (miRDB, microRNA.org and Targetscan) and qPCR, mRNA targets YY1, KLF9, KLF12 and MEX3C were identified as candidate targets for let-7d-3p and were significantly downregulated by let-7d-3p mimic. This suggests that let-7d-3p may play a role in signaling pathways pertinent to cardiac development (YY1), cell proliferation/survival (KLF9 and KLF12) and adiposity (Mex3c).
Conclusions:
We identified miRNAs that were dysregulated in clinical HF and our preliminary data on let-7d-3p suggests roles in the pathophysiology of HF that warrant further investigation.
Collapse
Affiliation(s)
- Lee Lee Wong
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Eng Leng Saw
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Yue Zhou
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Peipei Wang
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Arthur M Richards
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| |
Collapse
|
29
|
Wong LL, Saw EL, Lew KS, Rademaker MT, Ellmers LJ, Charles CJ, Richards AM, Wang P. Abstract 265: Identification of MicroRNA in an Ovine Model of Heart Failure. Circ Res 2016. [DOI: 10.1161/res.119.suppl_1.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
The sheep (
Ovis aries
) provides a large animal model in cardiovascular research including heart failure (HF). However, microRNA (miR) related work in the sheep model has been limited due to a paucity of information regarding oar-miR. The aim of this study was to identify novel oar-miRs in myocardium and examine their regulation in HF and HF recovery.
Methods:
Heart tissue was harvested from sheep undergoing 1. HF induced by rapid left ventricular (LV) pacing at 225bpm for 14 days, 2. HF recovery (HF-R) after discontinuation of pacing for an additional 14 days and 3. Sham. LV miRs were examined using next generation deep sequencing (NGS), miR array and stem-loop qPCR. Sequences were aligned with miRBase v20.0 and mapped to ovine genome and miRBase Mature BLAST search engine. Plasma was collected to assess natriuretic peptides (ANP and BNP).
Results:
Three miR libraries were generated from NGS and a total of 619 miRs were detected. Of these, 93 were oar-miRs; 49 novel miRs (high confidence) mapped to ovine genome and perfectly aligned to mature miRs in other organisms (miRBase v20.0); 69 putative novel miRs (high confidence) that mapped to ovine genome and aligned partially to mature miRs of other species in miRBase v20.0; 168 miRs (low confidence) that mapped to ovine genome but unaligned to any known mature miRs; and 240 miRs (low confidence) that were unmapped to the sheep genome but aligned to either miRBase mature hsa-/mmu-/rno-miRs. Plasma BNP and ANP increased 19-folds and 18- folds respectively in HF, and returned to baseline in HF-R. MiR levels in HF model were examined using miR array. About 1000 miRs were detected from array and at least 301 of them were overlapped with NGS data. Using miR array profiling followed by stem-loop qPCR validation, we found that myocardial enriched miR-133b-3p, miR-208b-3p, miR-21-5p and miR-125a-5p, -125b-5p, -126-3p, -210-3p, and 29a-3p were significantly upregulated in HF (p<0.05 vs. Sham). All trended downwards towards baseline levels during recovery (HF-R) but only miR-210 was significant (p<0.001 vs. HF).
Conclusion:
We identified 118 novel oar-miRs with high confidence and 408 potential oar-miRs, which is a solid foundation for miR function studies using sheep models. We also identified miR changes in HF and HF-R.
Collapse
Affiliation(s)
- Lee Lee Wong
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Eng Leng Saw
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Kar Sheng Lew
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Miriam T Rademaker
- Christchurch Heart Institute, Dept of Medicine, Univ of Otago, Christchurch, New Zealand
| | - Leigh J Ellmers
- Christchurch Heart Institute, Dept of Medicine, Univ of Otago, Christchurch, New Zealand
| | - Christopher J Charles
- Christchurch Heart Institute, Dept of Medicine, Univ of Otago, Christchurch, New Zealand
| | - Arthur M Richards
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Peipei Wang
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| |
Collapse
|
30
|
Zhou Y, Richards AM, Wang P. Abstract 100: Discovery of Cardiac Fibroblast Enriched microRNAs and Their Pivotal Roles in the Regulation of Cardiac Remodeling and Fibrosis. Circ Res 2016. [DOI: 10.1161/res.119.suppl_1.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cardiac fibroblast (cFB) responses to cardiac injury or overload directly contribute to deterioration of cardiac function in heart failure. MicroRNAs (miR) target multiple genes in cell signaling networks and are likely to have pivotal regulatory roles with respect to cFB function. To date cFB enriched miRs have not been reported. We have identified cFB enriched miRs which we hypothesize direct cFB proliferation and differentiation. Neonatal and adult rat cardiomyocytes (CM) and cFBs were isolated and cultured.
In vivo
and
in vitro
cardiac ischemic models comprised coronary artery ligation induced myocardial infarction (MI) in rats and cultured cFB exposed to hypoxia. RNA and protein were extracted for miR microarray, qPCR and Western Blot. Adult cFB transfected with miR mimics were tested for CCK-8 proliferation assay. Fifteen dysregulated miRs were selected from array profiles and qPCR validation. Among them miR-31, -199a, -214 and -222 were highly expressed in adult cFBs 10-90 folds vs. CM. CM specific miR-208a and 133a were undetectable in cFB. Neonatal cells showed directionally concordant but less pronounced differences. In early MI, cardiac miR-31 was up-regulated >30 fold vs. Sham (infarct), others increased 6-12 folds. All changes were ranked infarct>border>remote area. As a control, non-cFB enriched miR-125a remained unchanged. Hypoxia treatment of cFB
in vitro
up-regulated miR-31 but not the other miRs. Functional study by mimic transfection revealed differential roles of the miRs. MiR-31 increased cFB proliferation in CCK8 assay. MiR-199a and -222 had opposite effects. MiR-199a, but not miR-222, reversed the pro-fibrotic effects of TGF-β. MiR-199a reduced mRNA and protein expression of alpha smooth muscle actin (α-SMA), a myoFB differentiation marker and connective tissue growth factor (CTGF), a predicted target (miRDB). Conversely miR-31 increased α-SMA and CTGF. We provide the first report of 4 cFB enriched miRs and demonstrated their pro- vs. anti-fibrotic roles
in vitro
(miR-31 vs. miR-199 and -222 respectively). In early MI, the increase of pro-fibrotic miR-31 was predominant, whilst other miR dysregulation was secondary to cFB proliferation. cFB enriched miRs determine cFB fate and progression of cardiac fibrosis/remodeling.
Collapse
Affiliation(s)
- Yue Zhou
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Arthur M Richards
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| | - Peipei Wang
- Cardiovascular Rsch Institute, National Univ of Singapore, Singapore, Singapore
| |
Collapse
|
31
|
Chan MM, Santhanakrishnan R, Chong JP, Chen Z, Tai BC, Liew OW, Ng TP, Ling LH, Sim D, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Wong RCC, Chai P, Low AF, Richards AM, Lam CS. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2015; 18:81-8. [DOI: 10.1002/ejhf.431] [Citation(s) in RCA: 101] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Revised: 08/23/2015] [Accepted: 09/14/2015] [Indexed: 12/16/2022] Open
Affiliation(s)
- Michelle M.Y. Chan
- SingHealth Internal Medicine Residency Program, Singapore Health Services; Singapore
| | | | - Jenny P.C. Chong
- Cardiovascular Research Institute; National University of Singapore; Singapore
| | - Zhaojin Chen
- Investigational Medicine Unit; National University Health System Singapore; Singapore
| | - Bee Choo Tai
- Saw Swee Hock School of Public Health; National University of Singapore; Singapore
| | - Oi Wah Liew
- Cardiovascular Research Institute; National University of Singapore; Singapore
| | - Tze Pin Ng
- Yong Loo Lin School of Medicine; National University of Singapore; Singapore
| | - Lieng H. Ling
- Yong Loo Lin School of Medicine; National University of Singapore; Singapore
| | - David Sim
- National Heart Centre Singapore; Singapore
| | | | | | | | - Fazlur Jaufeerally
- Singapore General Hospital and Duke-NUS Graduate Medical School; Singapore
| | | | - Ping Chai
- National University Heart Centre Singapore; Singapore
| | - Adrian F. Low
- Yong Loo Lin School of Medicine; National University of Singapore; Singapore
| | - Arthur M. Richards
- Cardiovascular Research Institute; National University of Singapore; Singapore
- Yong Loo Lin School of Medicine; National University of Singapore; Singapore
| | - Carolyn S.P. Lam
- Cardiovascular Research Institute; National University of Singapore; Singapore
- Yong Loo Lin School of Medicine; National University of Singapore; Singapore
- Christchurch Heart Institute, University of Otago; Christchurch New Zealand
| |
Collapse
|
32
|
Wang P, Chen Q, Richards AM. Abstract 318: Targeting of Tp53inp1 by Mir-221 to Reduce P62-mediated Autophagy is Cardioprotective in Ischemia / Reperfusion Injury. Circ Res 2015. [DOI: 10.1161/res.117.suppl_1.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose:
Tumor protein 53-induced nuclear protein 1 (Tp53inp1) acts as a tumor suppressor by inducing cell death. Tp53inp1 mRNA is a predicted target of miR-221. Whether targeting Tp53inp1 plays a role in miR-221-mediated cardioprotection has not been investigated. We hypothesized that miRNA-221 directly targets Tp53inp1 to reduce ischemia/reperfusion (I/R)-induced autophagy.
Method:
Myoblast H9c2 cells underwent 16 hours 0.2% O
2
hypoxia followed by 2 hours re-oxygenation (H-R, simulating I/R). H9c2 were transfected with miRNA-221 mimic (25 nmol) and scrambled mimic control (miR-221 and MC). Cell count/viability, WST assay, cell injury-induced LDH release, and GFP-LC3 labeled autophagosome formation were measured. Cells were collected for RT-qPCR and western blot (WB) analyses. pCMV-Myc-Tp53inp1 and pcDNA3.1-Flag-p62 plasmids were cloned and transfected into H9c2 for recovery and immuno-precipitation (IP) studies. The effects of miRNA-221 inhibitor in H9c2 were also assessed.
Results:
miR-221 significantly reduced H-R injury as indicated by higher cell count/viability and WST activity, and reduced LDH (miR-221 vs. MC p<0.05). qPCR confirmed that (1) miRNA-221 expression was reduced in H-R; (2) RISC-loaded (IP pull-down Ago-2) miRNA-221 increased by ~80 fold and reduced by 95% following mimic and inhibitor transfection respectively; (3) Increased Tp53inp1 following H-R was reversed by miR-221. miR-221 inhibited H-R induced autophagosome formation (GFP-LC3). WB indicated (1) increase of LC3-I/II ratio and p62, indicators of reduced autophagy, and (2) decrease of Tp53inp1 by miR-221. IP pull-down Myc-Tp53inp1 indicated the formation of p62-Tp53inp1 complex. The protective effect of miR-221 was abolished by Tp53inp1 overexpression (pCMV-Myc-Tp53inp1 and miRNA-221 mimic co-transfection). The protective effect was corroborated in neonatal rat ventricular myocytes (NRVM). MiRNA-221 inhibitor induced reverse effects.
Conclusion:
The cardioprotection of miR-221 entails direct targeting of Tp53inp1 which reducing p62-Tp53inp1 complex formation and inhibiting H-R-induced autophagy.
Collapse
Affiliation(s)
- Peipei Wang
- National Univ of Singapore, Singapore, Singapore
| | | | | |
Collapse
|
33
|
Wang P, Chen Q, Zhou Y, Richards AM. Abstract 319: Mirna-125b Reduces Ischemia / Reperfusion (i/r)-induced Apoptosis Through Targeting Multiple Targets in Intrinsic and Extrinsic Apoptosis Pathways. Circ Res 2015. [DOI: 10.1161/res.117.suppl_1.319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Apoptosis is mediated through extrinsic and intrinsic pathways, both play a role in ischemia/reperfusion (I/R) injury. Predicted targets for miRNA-125b include extrinsic pathway mediators Traf6 and Tnfrsf1b, and intrinsic mitochondria regulators Bcl-2 family pro-apoptotic effectors Bak1 and BH3-only facilitators Bim, Bmf, Puma. We hypothesized that miRNA-125b directly targets multiple genes to reduce I/R-induced apoptosis. Myoblast H9c2 cells underwent 16 hours 0.2% O
2
hypoxia followed by 2 hours re-oxygenation (H-R, simulating I/R) and were transfected with miRNA-125b mimic vs. scrambled mimic control (25 nmol, miR-125b-M vs. MC) and miR-125b inhibitor vs. inhibitor control (miR-125b-I vs. IC). Cell count/viability, WST assay, cell injury-induced LDH release and apoptotic marker Casp3/7 were measured. Cells were trypsinized for assessment of apoptosis (7-AAD and annexin V double staining) and lysed for RT-qPCR and western blot (WB) analyses. pCMV-Myc-Bak1 plasmids were cloned and transfected into H9c2 for recovery studies. The effects were verified in neonatal rat ventricular myocytes (NRVM). miRNA-125b-M significantly reduced H-R injury as indicated by higher cell count/viability and WST activity, and reduced LDH (miR-125b-M vs. MC p<0.05). qPCR confirmed that (1) miR-125b expression was reduced in H-R; (2) RISC-loaded (immunoprecipitation pull-down Ago-2) miR-125b increased by ~35 fold and reduced to ~3% following mimic and inhibitor transfection respectively; (3) multiple apoptosis-related genes were reduced by miR-125b-M, Bak1, Bmf, Bim, Puma, Traf6 and Tnfrsf1b. All changes were confirmed by WB. Luciferase reporter assays indicated miR-125b bound to the 3’-UTR of all genes tested except Traf6. Total apoptotic cell numbers and Casp3/7 release were significantly reduced by miR-125b-M. The protective effect of miRNA-125b was partially abolished by Bak1 overexpression (pCMV-Myc-Bak1 and miR-125b co-transfection). Protective effects of miRNA-125b were further verified in NRVM. MiRNA-125b inhibitor reversed protective effects and target changes at mRNA and protein level. miR-125b is powerfully cardioprotective in I/R injury due to directly targeting multiple genes in the extrinsic and intrinsic apoptotic pathways.
Collapse
Affiliation(s)
- Peipei Wang
- National Univ of Singapore, Singapore, Singapore
| | | | - Yue Zhou
- National Univ of Singapore, Singapore, Singapore
| | | |
Collapse
|
34
|
Li RG, Lee CH, Low A, Chan M, Chan KH, Richards AM, Qu XK, Fang WY, Tan HC. Comparison of platinum chromium everolimus-eluting stent with cobalt chromium everolimus-eluting stent in unselected patients undergoing percutaneous coronary intervention. Eur Rev Med Pharmacol Sci 2015; 19:2213-2220. [PMID: 26166645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
OBJECTIVE The recent PLATINUM trial has demonstrated that the use of the new generation platinum chromium everolimus-eluting stents (PtCr-EES) yield clinical outcomes similar to those obtained by the use of cobalt chromium everolimus-eluting stents (CoCr-EES) in selected patients with 1 or 2 de novo coronary artery lesions. This study aimed to compare the safety and efficacy of the PtCr-EES and CoCr-EES in unselected patients from a real-life single-center registry. PATIENTS AND METHODS From July 2009 through November 2010, 788 consecutive patients in our institution with symptomatic coronary artery disease who were treated with the CoCr-EES (n = 410) or PtCr-EES (n = 378) were enrolled into this study. The primary endpoint of the study was target-lesion failure (TLF) at 12-month follow-up and the secondary endpoints were major adverse cardiovascular events and stent thrombosis. RESULTS The prevalence of TLF in the PtCr-EES group (4.5%) was similar to that in the CoCr-EES group (3.9%). In addition, there were no significant differences in the 12-month rates of cardiac death (2.1% vs. 1.5%), myocardial infarction (2.4% vs. 3.9%), ischemia-driven target lesion revascularization (2.4% vs. 2.2%), and definite or probable stent thrombosis (0.5% vs. 1.5%, all p > 0.05). CONCLUSIONS At 12-month follow-up, the PtCr-EES is comparable in safety and efficacy to the CoCr-EES in unselected patients with coronary artery diseases.
Collapse
Affiliation(s)
- R-G Li
- Department of Cardiology, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Nedoboy PE, Morgan PE, Mocatta TJ, Richards AM, Winterbourn CC, Davies MJ. High plasma thiocyanate levels are associated with enhanced myeloperoxidase-induced thiol oxidation and long-term survival in subjects following a first myocardial infarction. Free Radic Res 2015; 48:1256-66. [PMID: 25050609 DOI: 10.3109/10715762.2014.947286] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Elevated levels of myeloperoxidase (MPO) are associated with poor cardiovascular outcomes. MPO uses H2O2 to generate oxidants including HOCl and HOSCN, from chloride and thiocyanate (SCN(-)) ions, respectively. SCN(-) is the preferred substrate. Elevation of this anion decreases HOCl generation and increases HOSCN formation, a thiol-specific oxidant. Such changes are of potential relevance to people with elevated SCN(-) levels, such as smokers. In this retrospective study, we examined whether elevated plasma MPO and SCN(-) levels increased thiol oxidation as a result of increased HOSCN formation, and impacted on long-term survival in 176 subjects (74 non-smokers, 46 smokers, and 56 previous smokers) hospitalized after a first myocardial infarction. Plasma thiols were not significantly altered in smokers compared to non-smokers or past smokers. However, significant positive correlations were detected between SCN(-) levels and MPO-induced thiol loss in the total population (r = 0.19, P = 0.020) and smokers alone (r = 0.58, P < 0.0001). Twelve-year all-cause mortality data indicate that above median MPO is significantly associated with higher mortality, but below-median MPO and above-median SCN(-) results in increased survival, compared to below-median SCN(-). Cox proportional hazard analysis showed a significant decrease in mortality for each 1 μM increase in SCN(-) (0.991; P = 0.040). Subject age was, as expected, a strong predictor of subject survival. Overall these data suggest that subjects with below-median MPO and above-median SCN(-) have better long-term survival, and that elevated plasma levels of SCN(-) might be protective in at least some populations.
Collapse
Affiliation(s)
- P E Nedoboy
- The Heart Research Institute , Newtown, Sydney , Australia
| | | | | | | | | | | |
Collapse
|
36
|
Earle NJ, Poppe KK, Pilbrow AP, Cameron VA, Troughton RW, Skinner JR, Love DR, Shelling AN, Whalley GA, Ellis CJ, Richards AM, Doughty RN. Genetic markers of repolarization and arrhythmic events after acute coronary syndromes. Am Heart J 2015; 169:579-86.e3. [PMID: 25819866 DOI: 10.1016/j.ahj.2014.11.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2014] [Accepted: 11/21/2014] [Indexed: 01/09/2023]
Abstract
BACKGROUND There is a genetic contribution to the risk of ventricular arrhythmias in survivors of acute coronary syndromes (ACS). We wished to explore the role of 33 candidate single nucleotide polymorphisms (SNPs) in prolonged repolarization and sudden death in patients surviving ACS. METHODS A total of 2,139 patients (1680 white ethnicity) surviving an admission for ACS were enrolled in the prospective Coronary Disease Cohort Study. Extensive clinical, echocardiographic, and neurohormonal data were collected for 12 months, and clinical events were recorded for a median of 5 years. Each SNP was assessed for association with sudden cardiac death (SCD)/cardiac arrest (CA) and prolonged repolarization at 3 time-points: index admission, 1 month, and 12 months postdischarge. RESULTS One hundred six SCD/CA events occurred during follow-up (6.3%). Three SNPs from 3 genes (rs17779747 [KCNJ2], rs876188 [C14orf64], rs3864180 [GPC5]) were significantly associated with SCD/CA in multivariable models (after correction for multiple testing); the minor allele of rs17779747 with a decreased risk (hazard ratio [HR] 0.68 per copy of the minor allele, 95% CI 0.50-0.92, P = .012), and rs876188 and rs386418 with an increased risk (HR 1.52 [95% CI 1.10-2.09, P = .011] and HR 1.34 [95% CI 1.04-1.82, P = .023], respectively). At 12 months postdischarge, rs10494366 and rs12143842 (NOS1AP) were significant predictors of prolonged repolarization (HR 1.32 [95% CI 1.04-1.67, P = .022] and HR 1.30 [95% CI 1.01-1.66, P = .038], respectively), but not at earlier time-points. CONCLUSION Three SNPs were associated with SCD/CA. Repolarization time was associated with variation in the NOS1AP gene. This study demonstrates a possible role for SNPs in risk stratification for arrhythmic events after ACS.
Collapse
Affiliation(s)
- N J Earle
- Department of Medicine, University of Auckland, Auckland, New Zealand.
| | - K K Poppe
- Department of Medicine, University of Auckland, Auckland, New Zealand
| | - A P Pilbrow
- Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
| | - V A Cameron
- Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
| | - R W Troughton
- Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
| | - J R Skinner
- Greenlane Pediatric and Congenital Cardiac Services, Starship Childrens Hospital, Auckland, New Zealand
| | - D R Love
- Diagnostic Genetics, LabPlus, Auckland City Hospital, Auckland, New Zealand
| | - A N Shelling
- Department of Obstetrics and Gynecology, University of Auckland, Auckland, New Zealand
| | - G A Whalley
- Faculty of Social and Health Sciences, Unitec, Auckland, New Zealand
| | - C J Ellis
- Department of Medicine, University of Auckland, Auckland, New Zealand
| | - A M Richards
- Christchurch Heart Institute, University of Otago, Christchurch, New Zealand; Cardiovascular Research Institute, National University of Singapore, Singapore
| | - R N Doughty
- Department of Medicine, University of Auckland, Auckland, New Zealand
| |
Collapse
|
37
|
Richards AM, Abu Kwaik Y, Lamont RJ. Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity. Mol Oral Microbiol 2014; 30:2-15. [PMID: 25052812 DOI: 10.1111/omi.12072] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/18/2014] [Indexed: 01/20/2023]
Abstract
Actinetobacter baumannii is an important nosocomial pathogen that can cause a wide range of serious conditions including pneumonia, meningitis, necrotizing fasciitis and sepsis. It is also a major cause of wound infections in military personnel injured during the conflicts in Afghanistan and Iraq, leading to its popular nickname of 'Iraqibacter'. Contributing to its success in clinical settings is resistance to environmental stresses such as desiccation and disinfectants. Moreover, in recent years there has been a dramatic increase in the number of A. baumannii strains with resistance to multiple antibiotic classes. Acinetobacter baumannii is an inhabitant of oral biofilms, which can act as a reservoir for pneumonia and chronic obstructive pulmonary disease. Subgingival colonization by A. baumannii increases the risk of refractory periodontitis. Pathogenesis of the organism involves adherence, biofilm formation and iron acquisition. In addition, A. baumannii can induce apoptotic cell death in epithelial cells and kill hyphal forms of Candida albicans. Virulence factors that have been identified include pili, the outer membrane protein OmpA, phospholipases and extracellular polysaccharide. Acinetobacter baumannii can sense blue light through a blue-light sensing using flavin (BLUF) domain protein, BlsA. The resulting conformational change in BlsA leads to changes in gene expression, including virulence genes.
Collapse
Affiliation(s)
- A M Richards
- Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY, USA
| | | | | |
Collapse
|
38
|
Martinez EC, Lilyanna S, Vardy LA, Armugam A, Jeyaseelan K, Richards AM. Abstract 107: MicroRNA-31: A Novel Therapeutic Target for Ischemic Heart Disease. Circ Res 2014. [DOI: 10.1161/res.115.suppl_1.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
MicroRNAs (miRNA), small sequences of non-coding RNA which interact with complementary sequences on the 3’untranslated region of target messenger RNAs to modulate translation, have a pivotal role in the development of the heart and its response to injury. Myocardial infarction (MI) triggers a dynamic miRNA response with the potential of yielding therapeutic targets. Following miRNA array profiling in rat hearts 2, 7 and 14 days after MI induced by coronary ligation, we identified a progressive time-dependent up-regulation of miR-31 compared to sham rats. Increase of miR-31 in heart tissue in the acute and subacute phases after MI (up to 90-fold) was also detected by Real-Time PCR (P=0.02 at day 2; P<0.0001 at days 7 and 14, vs. sham). We found that miR-31 has a repressive effect on tissue mRNA expression of cardiac troponin-T (TNNT2), E2F transcription factor 6 (E2F6) and mineralocorticoid receptor (NR3C2). Reporter gene assays showed that miR-31 targets the 3′UTR of these genes, with a marked repressive effect on TNNT2. In vitro, exposure to hypoxia significantly induced the expression of miR-31 in neonatal rat cardiomyocytes (nRCM), rat cardiac fibroblasts (nRCF) and cardiomyoblasts (H9C2) and suppressed the expression of TNNT2, E2F6 and NR3C2 in nRCM and H9C2 cells, and of E2F6 and NR3C2 in nRCF. LNA-based oligonucleotide inhibition of miR-31(miR-31i) in vitro reversed its repressive effect on translation from target genes. Therapeutic modulation of miR-31 expression in vivo after MI via subcutaneous administration of miR-31i (25mg/Kg/q2w) in rats, led to cardiac repression of miR-31 and subsequent enhanced expression of target genes. Also, miR-31i led to preservation of cardiac function and structure by day 14 after treatment. An absolute 10% improvement in left ventricular (LV) ejection fraction (EF) was observed in miR-31i-treated rats from day 2 to 16 after MI, while control rats that received scrambled LNA inhibitor or placebo displayed 23% deterioration in EF (n=6-8/group, P<0.0001). We conclude that miR-31 induction after MI is deleterious to cardiac function and plays an important role in adverse remodeling, while its therapeutic inhibition in vivo ameliorates cardiac dysfunction and prevents the development of post-ischemic heart failure.
Collapse
Affiliation(s)
| | | | - Leah A Vardy
- A*STAR Institute of Med Biology, Singapore, Singapore
| | | | | | | |
Collapse
|
39
|
de Carvalho LP, Gao F, Chen Q, Hartman M, Sim LL, Koh TH, Foo D, Chin CT, Ong HY, Tong KL, Tan HC, Yeo TC, Yew CK, Richards AM, Peterson ED, Chua T, Chan MY. Differences in late cardiovascular mortality following acute myocardial infarction in three major Asian ethnic groups. Eur Heart J Acute Cardiovasc Care 2014; 3:354-62. [PMID: 24598820 DOI: 10.1177/2048872614527007] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AIM the purpose of this study was to investigate differences in long-term mortality following acute myocardial infarction (AMI) in patients from three major ethnicities of Asia. METHODS AND RESULTS We studied 15,151 patients hospitalized for AMI with a median follow-up of 7.3 years (maximum 12 years) in six publicly-funded hospitals in Singapore from 2000-2005. Overall and cause-specific cardiovascular (CV) mortality until 2012 were compared among three major ethnic groups that represent large parts of Asia: Chinese, Malay and Indian. Relative survival of all three ethnic groups was compared with a contemporaneous background reference population using the relative survival ratio (RSR) method. The median global registry of acute coronary events score was highest among Chinese, followed by Malay and Indians: 144 (25th percentile 119, 75th percentile 173), 138 (115, 167), and 131 (109, 160), respectively, p<0.0001; similarly, in-hospital mortality was highest among Chinese (9.8%) followed by Malay (7.6%) and Indian (6.4%) patients. In contrast, 12-year overall and cause-specific CV mortality was highest among Malay (46.2 and 32.0%) followed by Chinese (43.0 and 27.0%) and Indian (35.9 and 25.2%) patients, p<0.0001. The five-year RSR was lowest among Malay (RSR 0.69) followed by Chinese (RSR 0.73) and Indian (RSR 0.79) patients, compared with a background reference population (RSR 1.00). CONCLUSIONS We observed strong inter-Asian ethnic disparities in long-term mortality after AMI. Malay patients had the most discordant relationship between baseline risk and long-term mortality. Intensified interventions targeting Malay patients as a high-risk group are necessary to reduce disparities in long-term outcomes.
Collapse
Affiliation(s)
| | - Fei Gao
- National Heart Centre, Singapore Duke-NUS Graduate Medical School, Singapore
| | | | - Mikael Hartman
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore Department of Surgery, National University of Singapore, Singapore
| | | | | | | | | | | | | | - Huay-Cheem Tan
- National University Heart Centre, National University of Singapore, Singapore
| | - Tiong-Cheng Yeo
- National University Heart Centre, National University of Singapore, Singapore
| | - Chow-Khuan Yew
- National Registry of Disease Office, Health Promotion Board, Singapore
| | - Arthur M Richards
- National University Heart Centre, National University of Singapore, Singapore
| | | | | | - Mark Y Chan
- National University Heart Centre, National University of Singapore, Singapore
| |
Collapse
|
40
|
Tan ES, Xu CF, Feng L, Santhanakrishnan R, Chan MMY, Seow SC, Ching CK, Richards AM, Ng TP, Lam CS. PT015 Association of Ethnicity, Age and Body Size with Electrocardiographic Values in the Community. Glob Heart 2014. [DOI: 10.1016/j.gheart.2014.03.1826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
41
|
Stamp LK, Wells JE, Pitama S, Faatoese A, Doughty RN, Whalley G, Richards AM, Cameron VA. Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities. Intern Med J 2014; 43:678-84. [PMID: 23279108 DOI: 10.1111/imj.12062] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2012] [Accepted: 12/03/2012] [Indexed: 01/23/2023]
Abstract
BACKGROUND There are few current data on the prevalence of hyperuricaemia and gout in New Zealand, particularly among the indigenous Māori population. AIMS To determine the prevalence of gout and hyperuricaemia in rural and urban Māori and non-Māori community samples and describe the treatment and comorbidities of participants with gout. METHODS Participants aged 20-64 years were recruited by random selection from the electoral roll. Māori samples were selected from among those identified as being of Māori descent on the roll and who self-identified as being of Māori ethnicity at interview. Personal medical history, blood pressure, anthropometrics, fasting lipids, glucose, HbA1c and urate were recorded. RESULTS There were 751 participants. Mean serum urate (SU) was 0.30 mmol/L (0.06-0.69 mmol/L). Māori had a significantly higher prevalence of hyperuricaemia (SU > 0.40 mmol/L) compared with non-Māori (17.0% vs 7.5%, P = 0.0003). A total of 57 participants had a history of gout, with a higher prevalence in Māori compared with non-Māori (10.3% vs 2.3%, P < 0.0001). Of the participants, 18/57 (31.6%) with gout were receiving urate-lowering therapy, but in 38.9%, SU was >0.36 mmol/L. Participants with gout were more likely to have metabolic syndrome, diabetes, cardiac disease or hypertension. CONCLUSIONS Gout and hyperuricaemia were more prevalent in Māori, and participants with gout were more likely to have comorbidities. There was not a higher overall adjusted cardiovascular disease risk in Māori participants with gout. Despite the high prevalence of gout, management remains suboptimal.
Collapse
Affiliation(s)
- L K Stamp
- Department of Medicine, University of Otago, Christchurch, New Zealand.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Chan K, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, Burnett S, Vaccarino VL, Zafari AM, Shah SH, Anderson JL, Carlquist JF, Hartiala J, Allayee H, Hinohara K, Lee BS, Erl A, Ellis KL, Goel A, Schaefer AS, Mokhtari NE, Goldstein BA, Hlatky MA, Go AS, Shen GQ, Gong Y, Pepine C, Laxton RC, Wittaker JC, Tang WHW, Johnson JA, Wang QK, Assimes TL, Nöthlings U, Farrall M, Watkins H, Richards AM, Cameron VA, Muendlein A, Drexel H, Koch W, Park JE, Kimura A, Shen WF, Simpson IA, Hazen SL, Horne BD, Hauser ER, Quyyumi AA, Reilly MP, Samani NJ, Ye S. 126 CHROMOSOME 9P21 LOCUS AND ANGIOGRAPHIC CORONARY ARTERY DISEASE BURDEN: A COLLABORATIVE META-ANALYSIS. Heart 2013. [DOI: 10.1136/heartjnl-2013-304019.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Prickett TCR, Olney RC, Cameron VA, Ellis MJ, Richards AM, Espiner EA. Impact of age, phenotype and cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an adult population. Clin Endocrinol (Oxf) 2013; 78:783-9. [PMID: 22963390 DOI: 10.1111/cen.12035] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2012] [Revised: 06/14/2012] [Accepted: 09/03/2012] [Indexed: 11/28/2022]
Abstract
CONTEXT In contrast to the cardiac hormones, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), variations in plasma concentrations of C-type natriuretic peptide (CNP) in healthy adults are ill-defined, limiting their clinical application. OBJECTIVE Our objective was to define the effect of age, phenotype (gender, height, BMI), and cardiac and renal function on plasma CNPs in an adults population without renal or cardiovascular disease. DESIGN AND SETTING This was a prospective cross-sectional observational study of adult volunteers, aged 21-80 years, randomly selected from the electoral roll. SUBJECTS AND METHODS Plasma CNP and its associated aminoterminal propeptide (NTproCNP) were measured in 258 subjects and related to age, gender, height and plasma creatinine. Subgroup analyses seeking associations with cardiac function (plasma BNP and NTproBNP) and bone turnover bone-specific alkaline phosphatase (bALP) were also determined. RESULTS Plasma concentrations of CNPs in men continued to decline from adolescent values to reach a nadir in the 5th decade after which values increased. Similar but less marked changes occurred in women. In both sexes, NTproCNP was inversely and independently correlated with height. In contrast to B-type natriuretic peptides (BNPs), NTproCNP was higher in men, significantly related to creatinine and positively related to bALP. CONCLUSIONS Gender- and age-specific changes affect CNPs in adults. Inverse associations of NTproCNP with adult height, positive correlation with creatinine - and in contrast to CNP - no association with BNP are further unique findings distinguishing NTproCNP, which need to be considered in future studies.
Collapse
Affiliation(s)
- T C R Prickett
- Department of Medicine, University of Otago, Christchurch, New Zealand.
| | | | | | | | | | | |
Collapse
|
44
|
Patel K, Rademaker MT, Kirkpatrick CMJ, Charles CJ, Fisher S, Yandle TG, Richards AM. Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep. Br J Pharmacol 2012; 166:1916-25. [PMID: 22339174 DOI: 10.1111/j.1476-5381.2012.01904.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND AND PURPOSE The urocortin (Ucn) peptides are emerging as potential therapeutic targets for heart disease. However, pharmacokinetic (PK) and pharmacodynamic (PD) data are lacking. Therefore, we investigated the PK/PD for all three Ucns. EXPERIMENTAL APPROACH Seven sheep received 1 µg·kg(-1) boluses of Ucn1, Ucn2 and Ucn3. Population PK/PD models were developed to describe the time course of the haemodynamic effects. RESULTS The population estimate for Ucn1 clearance (0.486 L·h(-1)) was lower than that for Ucn2 (21.7 L·h(-1)) and Ucn3 (220 L·h(-1)), while steady-state volumes of distribution were similar for Ucn1 and Ucn2 (∼8 L) but substantially larger for Ucn3 (23.5 L). Ucn1 disposition was adequately described by a two-compartment model, with a one-compartment model required for Ucn2 and Ucn3. The half-life for Ucn1 was 2.9 h (α phase) and 8.3 h (β phase), and 15.7 and 4.4 min for Ucn2 and Ucn3 respectively. All Ucns produced significant increases in heart rate, cardiac output and left ventricular systolic and mean arterial pressures, and decreases in left atrial pressure and peripheral resistance. Delayed-effect pharmacodynamic models best described the time course of haemodynamic responses, with effects more rapid and less prolonged for Ucn2 and Ucn3 than Ucn1. Similar and physiologically plausible estimated baseline (E(0)) effects were exhibited by all Ucns, whereas EC(50) values were generally greater for Ucn1. CONCLUSIONS AND IMPLICATIONS Relative to Ucn1, both the PK and haemodynamic responses to Ucn2 and Ucn3 occurred more rapidly. Our data provide important comparative information, useful to the rational design of future clinical studies.
Collapse
Affiliation(s)
- K Patel
- The School of Pharmacy, The University of Queensland, Pharmacy Australia Centre of Excellence, Brisbane, Australia
| | | | | | | | | | | | | |
Collapse
|
45
|
Ellis KL, Palmer BR, Frampton CM, Troughton RW, Doughty RN, Whalley GA, Ellis CJ, Pilbrow AP, Skelton L, Yandle TG, Richards AM, Cameron VA. Genetic variation in the renin-angiotensin-aldosterone system is associated with cardiovascular risk factors and early mortality in established coronary heart disease. J Hum Hypertens 2012; 27:237-44. [PMID: 22739771 DOI: 10.1038/jhh.2012.24] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
This study examined renin-angiotensin-aldosterone (RAAS) system gene variants for associations with cardiovascular risk factors and outcomes in coronary heart disease. Coronary disease patients (n=1186) were genotyped for 21 single-nucleotide polymorphisms (SNPs) within angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin-II type-1 receptor (AGTR1) and aldosterone synthase (CYP11B2). Associations with all-cause mortality and cardiovascular readmissions were assessed over a median of 3.0 years. The AGT M235T 'T' allele was associated with a younger age of clinical coronary disease onset (P=0.006), and the AGT rs2478545 minor allele was associated with lower circulating natriuretic peptides (P=0.0001-P=0.001) and E/E(1) (P=0.018). Minor alleles of AGT SNPs rs1926723 and rs11122576 were associated with more frequent history of renal disease (P0.04) and type-2 diabetes (P0.02), higher body mass index (P0.02) and greater mortality (P0.007). AGT rs11568054 minor allele carriers had more frequent history of renal disease (P=0.04) and higher plasma creatinine (P=0.033). AGT rs6687360 minor allele carriers exhibited worse survival (P=0.02). ACE rs4267385 was associated with older clinical coronary disease onset (P=0.008) and hypertension (P=0.013) onset, increased plasma creatinine (P=0.01), yet greater mortality (P=0.044). Less history of hypertension was observed with the AGTR1 rs12685977 minor allele (P=0.039). Genetic variation within the RAAS was associated with cardiovascular risk factors and accordingly poorer survival.
Collapse
Affiliation(s)
- K L Ellis
- Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago-Christchurch, Christchurch, New Zealand.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Prickett TCR, Bothwell JC, Yandle TG, Richards AM, Espiner EA. Pharmacodynamic responses of plasma and tissue C-type natriuretic peptide to GH: correlation with linear growth in GH-deficient rats. J Endocrinol 2012; 212:217-25. [PMID: 22087017 DOI: 10.1530/joe-11-0387] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Studies from genetic modification and spontaneous mutations show that C-type natriuretic peptide (CNP) signalling plays an essential part in postnatal endochondral growth, but measurement of CNP proteins and changes in their abundance in tissues and plasma during normal growth has not been reported. Using rodent pups with GH deficiency, we now describe the pharmacodynamic response of CNP and rat amino-terminal proCNP (NTproCNP) in plasma and tissues, and relate these to changes in linear growth (nose-tail length, tibial length and tibial growth plate width) during the course of 1 week of GH or saline (control) administration. Compared with saline, significant increases in plasma and tissue CNP forms were observed after 24 h in GH-treated pups and before any detectable change in linear growth. Whereas CNP abundance was increased in most tissues (muscle, heart and liver) by GH, enrichment was the greatest in extracts from growth plates and kidney. Plasma and tissue concentrations in GH-treated pups were sustained or further increased at 1 week when strong positive associations were found between plasma NTproCNP and linear growth or tissue concentrations. High content of NTproCNP in kidney tissue strongly correlated with plasma concentrations, which is consistent with previous data showing renal extraction of the peptide. In showing a prompt and significant increase in CNP in tissues driving normal endochondral growth, these findings provide further rationale for CNP agonists in the treatment of growth disorders resistant to current therapies and support the use of CNP concentrations as biomarkers of linear growth.
Collapse
Affiliation(s)
- T C R Prickett
- Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch 8140, New Zealand.
| | | | | | | | | |
Collapse
|
47
|
Palmer BR, Frampton CM, Skelton L, Yandle TG, Doughty RN, Whalley GA, Ellis CJ, Troughton RW, Richards AM, Cameron VA. KCNE5 polymorphism rs697829 is associated with QT interval and survival in acute coronary syndromes patients. J Cardiovasc Electrophysiol 2011; 23:319-24. [PMID: 21985337 DOI: 10.1111/j.1540-8167.2011.02192.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
INTRODUCTION The KCNE family is a group of small transmembrane channel proteins involved in potassium ion (K(+)) conductance. The X-linked KCNE5 gene encodes a regulator of the K(+) current mediated by the potassium channel KCNQ1. Polymorphisms in KCNE5 have been associated with altered cardiac electrophysiological properties in human studies. We investigated associations of the common rs697829 polymorphism from KCNE5 with baseline characteristics, baseline electrocardiographic (ECG) measurements, and patient survival in a cohort of post-acute coronary syndromes (ACS) patients (the Coronary Disease Cohort Study cohort). METHODS AND RESULTS DNA samples (n = 1,740) were genotyped for rs697829 using a TaqMan assay. Baseline ECG data revealed corrected QT (QTc) interval was associated with rs697829 in male, but not female, patients, being extended in the G genotype group (A 416 ± 1.71; G 431 ± 4.25 ms, P = 0.002). Covariate-adjusted survival was poorest in G genotype patients in Cox proportional hazard modeling of mortality data of males (P(overall) = 0.020). Male patients with G genotype had a hazard ratio of 1.44 (1.11-2.33) for death when compared to the A genotype male patients (P = 0.048) after adjustment for age, baseline log-transformed N-terminal pro-B-type natriuretic peptide (NTproBNP), β-blocker and insulin treatment, QTc interval, history of myocardial infarction, and physical activity score. CONCLUSION This study suggests an association between rs697829, a common single nucleotide polymorphism (SNP) from KCNE5, and ECG measurements and survival in postacute ACS patients. Prolonged subclinical QT interval may be a marker of adverse outcome in this group of patients.
Collapse
Affiliation(s)
- Barry R Palmer
- Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, New Zealand.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Prosser HC, Richards AM, Forster ME, Pemberton CJ. Regional vascular response to ProAngiotensin-12 (PA12) through the rat arterial system. Peptides 2010; 31:1540-5. [PMID: 20493224 DOI: 10.1016/j.peptides.2010.05.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2010] [Revised: 05/12/2010] [Accepted: 05/12/2010] [Indexed: 11/29/2022]
Abstract
ProAngiotensin-12 (PA12) is the most recent peptide to be identified as a functional component of the renin-angiotensin system (RAS). PA12 is reported to constrict rat coronary arteries and the aorta, dependent upon angiotensin II-converting enzyme 1 (ACE1) and chymase. The current study employed myography to determine the direct vascular effects of PA12 on a range of isolated rat arteries extending from the core to periphery. PA12 significantly constricted the descending thoracic aorta, right and left common carotid arteries, abdominal aorta and superior mesenteric artery, with little effect on the femoral and renal arteries. AngII was found to produce similar responses to PA12 when administered at the same dose. A potency gradient in response to PA12 was clearly apparent, with vessels in closest proximity to the heart responding with the greatest constriction; while constrictive potency was lost further form the heart. Inhibition of ACE1 and chymase both significantly attenuated PA12-induced vasoconstriction, with chymostatin displaying lesser potency. We postulate ACE1 primarily regulates RAS activity within the circulation, while chymase may have an important role in local, tissue-based RAS activity.
Collapse
Affiliation(s)
- H C Prosser
- Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2042, Australia.
| | | | | | | |
Collapse
|
49
|
Marshall CJ, Fisher S, Yandle TG, Smyth D, Elliott JM, Blake J, Richards AM, McClean DR. Trans-Cardiac Production of Urotensin II in Acute and Chronic Ischaemia. Heart Lung Circ 2009. [DOI: 10.1016/j.hlc.2009.04.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Mears SC, Richards AM, Knight TA, Belkoff SM. Subsidence of uncemented stems in osteoporotic and non-osteoporotic cadaveric femora. Proc Inst Mech Eng H 2008; 223:189-94. [DOI: 10.1243/09544119jeim445] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The increased use of uncemented stems for hip arthroplasty and of fast-recovery protocols in elderly patients make initial stem stability and resistance to fracture critical factors in osteoporotic bone. In this paper, the subsidence and failure of two uncemented stem designs (M/L Taper and VerSys Fullcoat, Zimmer, Inc, Warsaw, Indiana, USA) in osteoporotic and non-osteoporotic cadaveric femora were compared under simulated walking conditions (axial compression and external rotation). Osteoporotic femora implanted with either stem design failed significantly more frequently than did non-osteoporotic femora. Femora implanted with the M/L stems (seven of ten by 1000 cycles) fractured earlier than did femora implanted with the Fullcoat stem (one of ten by 1000 cycles). The use of early weight-bearing protocols with uncemented stem designs in osteoporotic bone should be approached with caution.
Collapse
Affiliation(s)
- S C Mears
- International Center for Orthopaedic Advancement, Department of Orthopaedic Surgery, The Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
| | - A M Richards
- International Center for Orthopaedic Advancement, Department of Orthopaedic Surgery, The Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
| | - T A Knight
- International Center for Orthopaedic Advancement, Department of Orthopaedic Surgery, The Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
| | - S M Belkoff
- International Center for Orthopaedic Advancement, Department of Orthopaedic Surgery, The Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
| |
Collapse
|